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Regulation of Luteinizing Hormone and Catecholamine Release
Abstract
These studies tested the interrelated hypotheses that the ovarian hormones produce their positive
feedback effects on luteinizing hormone (LH) secretion through activation of noradrenergic and
adrenergic systems in specific hypothalamic regions. Furthermore, the ovarian hormones may alter the
activity of opioid neuropeptide and Gamma-Aminobutyric Acid (GABA) systems to produce these
alterations in catecholamine transmission and gonadotropin secretion. Radioimmunoassays were utilized
to determine plasma LH and median eminence LHRH, and hypothalamic catecholamine concentrations
were measured by radioenzymatic assay.
The first two studies tested whether epinephrine (EPI) synthesis inhibition blocks the accumulation of
median eminence LHRH that precedes the ovarian hormone-induced LH surge and also to test whether
the stimulatory ovarian hormone regimen enhances the activity of hypothalamic EPI systems.
Ovariectomized rats were primed with estradiol (EB), followed 2 days later by progesterone (Prog.).
Animals were treated before Prog, administration with saline, one of the EPI synthesis inhibitors SKF
64139 or LY 78335, or the norepinephrine (NE) synthesis inhibitor, FLA-63. The catecholamine synthesis
inhibitors blocked or delayed the LH surge. FLA-63 completely prevented the accumulation of LHRH in the
median eminence that preceded the rise in LH release. However, selective reduction in EPI levels with SKF
64139 only partially prevented this increase in LHRH. A second EPI synthesis inhibitor, LY 78335, delayed
both the LH surge and the rise in LHRH.
In a second experiment, the administration of EB plus Prog, to ovariectomized rats increased the alphamethyltyrosine (aMT) induced depletion of EPI in the medial basal hypothalamus (MBH). The depletion of
NE after synthesis inhibition was enhanced in both the MBH and preoptic-anterior hypothalamus (POA).
Experiments 3 and 4 examined a possible mechanism underlying these ovarian hormone effects on LH
release and catecholamine activity. These studies tested whether the opiate antagonist, naloxone, which
increases LH release, enhances the activity of NE and EPI neurons in the hypothalamus, and also tested
whether morphine, an opiate agonist which decreases LH release, depresses the activity of hypothalamic
NE and EPI activity. Administration of naloxone to EB-primed rats increased LH release and potentiated
the depletion of NE in the POA and MBH, and enhanced the decline of EPI and dopamine (DA) in the MBH,
suggesting increased catecholamine activity in these regions. Administration of the opiate agonist,
morphine, to rats pretreated with EB and Prog., decreased LH and decreased the depletion of the
catecholamines in the POA and MBH, suggesting reduced activity. In most cases, naloxone antagonized
the inhibitory effect of morphine.
Experiments 3, 6, and 7 examined the involvement of (GABA) systems in the positive feedback effects of
EB and Prog, on LHRH and LH release. These studies tested 1) the effects of GABAergic drugs on the LH
surge induced by EB and Prog., 2) whether GABA agonists reduce NE and EPI activity in the
hypothalamus, and 3) whether a GABA agonist prevents the accumulation of median eminence LHRH
induced by EB and Prog. Ovariectomized rats received the stimulatory EB plus Prog, treatment.
Simultaneously with Prog., rats received either saline, the barbiturate, phenobarbital, the GABAg agonist,
baclofen, the GABA^ agonist, muscimol, or either the GABA^ antagonist, bicuculline, or the putative
GABAg antagonist, 5-aminovalerate. Additional experiments tested the effects of the GABA drugs on LH
release in ovariectomized, hormonally untreated rats and in response to exogenous LHRH. The LH surge
induced by EB+Prog. was blocked by treatment with either baclofen, muscimol, or phenobarbital.
Bicuculline was ineffective in preventing the effect of baclofen and phonobarbital but partially prevented
the effect of muscimol. Neither baclofen nor muscimol significantly affected LH release in hormonally
untreated, ovariectomized rats or in rats receiving LHRH administration. In the results of Experiment 6, in

EB plus Prog.-treated rats, baclofen and muscimol significantly reduced the concentrations of EPI and NE
in the POA and MBH and prevented their decline after administration of otMT, suggesting decreased
catecholamine transmission.
In Experiment 7, rats were primed with the ovarian hormones and received, concurrently with Prog., either
saline, or baclofen. The GABAg agonist, baclofen, blocked the LH surge and selectively increased LHRH
concentrations.
Experiment 8 tested 1) whether baclofen reverses the enhancement of LH release and catecholamine
activity produced by naloxone, and 2) whether the opiate antagonist, nalmefene, prevents the blockade of
the LH surge produced by baclofen. In the first study of Experiment 8, naloxone increased LH release and
enhanced catecholamine activity in EB-primed rats. Baclofen was unable to reverse these effects. In the
second study, baclofen administration to EB plus P treated rats blocked the LH surge and concomitant
administration of nalmefene was unable to prevent this effect of baclofen.
These results suggest that: 1) the ovarian hormones activate both NE and EPI systems to stimulate the
early afternoon rise of LHRH in the median eminence and to induce the subsequent LH surge, 2) the
ovarian hormones may produce their positive feedback effects on LH secretion by removing an inhibitory
GABA or opioid neuropeptide influence on catecholamine transmission, allowing NE and EPI to stimulate
LHRH, and subsequently, LH release, and 3) these modulatory actions of GABA and opiates may represent
effects of two parallel, yet independent hypothalamic systems which regulate catecholamine
neurotransmission and subsequently LH secretion.
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ABSTRACT
These studies tested the interrelated hypotheses that the ovarian
hormones produce their positive feedback effects on luteinizing hormone
(LH) secretion through activation of noradrenergic and adrenergic sys
tems in specific hypothalamic regions.

Furthermore, the ovarian hor

mones may alter the activity of opioid neuropeptide and Gamma-Amino
butyric Acid (GABA) systems to produce these alterations in catechola
mine transmission and gonadotropin secretion.

Radioimmunoassays were

utilized to determine plasma LH and median eminence LHRH, and hypotha
lamic catecholamine concentrations were measured by radioenzymatic
assay.
The first two studies tested whether epinephrine (EPI) synthesis
inhibition blocks the accumulation of median eminence LHRH that precedes
the ovarian hormone-induced LH surge and also to test whether the stimu
latory ovarian hormone regimen enhances the activity of hypothalamic EPI
systems.

Ovariectomized rats were primed with estradiol (EB), followed

2 days later by progesterone (Prog.).

Animals were treated before

Prog, administration with saline, one of the EPI synthesis inhibitors
SKF 64139 or LY 78335, or the norepinephrine (NE) synthesis inhibitor,
FLA-63.
LH surge.

The catecholamine synthesis inhibitors blocked or delayed the
FLA-63 completely prevented the accumulation of LHRH in the

median eminence that preceded the rise in LH release.

However, selec

tive reduction in EPI levels with SKF 64139 only partially prevented
this increase in LHRH.

A second EPI synthesis inhibitor, LY 78335,

delayed both the LH surge and the rise in LHRH.
iii
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In a second experiment, the administration of EB plus Prog, to
ovariectomized rats increased the alpha-methyltyrosine (aMT) induced
depletion of EPI in the medial basal hypothalamus (MBH).

The depletion

of NE after synthesis inhibition was enhanced in both the MBH and pre
optic-anterior hypothalamus (POA).
Experiments 3 and 4 examined a possible mechanism underlying these
ovarian hormone effects on LH release and catecholamine activity.

These

studies tested whether the opiate antagonist, naloxone, which increases
LH release, enhances the activity of NE and EPI neurons in the hypotha
lamus, and also tested whether morphine, an opiate agonist which
decreases LH release, depresses the activity of hypothalamic NE and EPI
activity.

Administration of naloxone to EB-primed rats increased LH

release and potentiated the depletion of NE in the POA and MBH, and
enhanced the decline of EPI and dopamine (DA) in the MBH, suggesting
increased catecholamine activity in these regions.

Administration of

the opiate agonist, morphine, to rats pretreated with EB and Prog.,
decreased LH and decreased the depletion of the catecholamines in the
POA and MBH, suggesting reduced activity.

In most cases, naloxone anta

gonized the inhibitory effect of morphine.
Experiments 3, 6, and 7 examined the involvement of (GABA) systems
in the positive feedback effects of EB and Prog, on LHRH and LH
release.

These studies tested 1) the effects of GABAergic drugs on the

LH surge induced by EB and Prog., 2) whether GABA agonists reduce NE and
EPI activity in the hypothalamus, and 3) whether a GABA agonist prevents

V

the accumulation of median eminence LHRH induced by EB and Prog.
Ovariectomized rats received the stimulatory EB plus Prog, treatment.
Simultaneously with Prog., rats received either saline, the barbiturate,
phenobarbital, the GABAg agonist, baclofen, the GABA^ agonist,
muscimol, or either the GABA^ antagonist, bicuculline, or the putative
GABAg antagonist, 5-aminovalerate.

Additional experiments tested the

effects of the GABA drugs on LH release in ovariectomized, hormonally
untreated rats and in response to exogenous LHRH.

The LH surge induced

by EB+Prog. was blocked by treatment with either baclofen, muscimol, or
phenobarbital.

Bicuculline was ineffective in preventing the effect of

baclofen and phonobarbital but partially prevented the effect of
muscimol.

Neither baclofen nor muscimol significantly affected LH

release in hormonally untreated, ovariectomized rats or in rats
receiving LHRH administration.

In the results of Experiment 6, in EB

plus Prog.-treated rats, baclofen and muscimol significantly reduced the
concentrations of EPI and NE in the POA and MBH and prevented their
decline after administration of otMT, suggesting decreased catecholamine
transmission.
In Experiment 7, rats were primed with the ovarian hormones and
received, concurrently with Prog., either saline, or baclofen.

The

GABAg agonist, baclofen, blocked the LH surge and selectively
increased LHRH concentrations.
Experiment 8 tested 1) whether baclofen reverses the enhancement of
LH release and catecholamine activity produced by naloxone, and 2)
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whether the opiate antagonist, nalmefene, prevents the blockade of the
LH surge produced by baclofen.

In the first study of Experiment 8,

naloxone increased LH release and enhanced catecholamine activity in
EB-primed rats.

Baclofen was unable to reverse these effects.

In the

second study, baclofen administration to EB plus P treated rats blocked
the LH surge and concomitant administration of nalmefene was unable to
prevent this effect of baclofen.
These results suggest that:

1) the ovarian hormones activate both

NE and EPI systems to stimulate the early afternoon rise of LHRH in the
median eminence and to induce the subsequent LH surge, 2) the ovarian
hormones may produce their positive feedback effects on LH secretion by
removing an inhibitory GABA or opioid neuropeptide influence on cate
cholamine transmission, allowing NE and EPI to stimulate LHRH, and sub
sequently, LH release, and 3) these modulatory actions of GABA and opi
ates may represent effects of two parallel, yet independent hypothalamic
systems which regulate catecholamine neurotransmission and subsequently
LH secretion.
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CHAPTER I

REVIEW OF THE LITERATURE
A.

Introduction
The estrous cycle of the female rat is characterized by the secre

tion of both ovarian (estrogen, progesterone) and adenohypophyseal
(luteinizing hormone, follicle stimulating hormone, prolactin) hormones
which are released in a specific pattern.

Plasma concentrations of

luteinizing hormone (LH) and prolactin are maintained at low levels dur
ing diestrus day 1 and 2 (1,2).

This tonic inhibition is interrupted on

proestrus by an afternoon surge in plasma levels of LH, follicle stimu
lating hormone, and prolactin (1,2,3).

These changes in anterior pitu

itary secretion are the result of the negative (inhibitory) and positive
(stimulatory) feedback effects of estradiol and progesterone (4).

The

feedback actions of the ovarian hormones could take place either in the
brain or the pituitary (4,5).
B.

Regulation of LH secretion by ovarian hormones
Circulating levels of estradiol and progesterone fluctuate during

the estrous cycle (2).

Progesterone, secreted by the corpora lutea,

rises during estrus and diestrus I and decreases during diestrus II.
Estradiol secretion also begins to increase on diestrus I and II.

Such

concentrations of estradiol act synergistcally with progesterone to pro
vide the tonic inhibition of LH during diestrus (21,22).

The acute

increase in LH release following ovariectomy and the ability of estra
diol to suppress it, support such a tonic inhibitory role for estradiol
1

2
during diestrus (57).

Estradiol concentrations continue to rise

continuously before peaking on proestrus morning (2, 3).

That such high

levels of estradiol are essential for the occurrence of the preovulatory
LH surge is suggested by studies in which an estrogen antagonist (23) or
estradiol antiserum (24,25) prevented the proestrous LH surge.
Estradiol thus appears to be indispensible for the proestrus LH surge to
occur, however, progesterone may not be since antiserum to progesterone
failed to block ovulation (24).

However, progesterone does play an

important role, in combination with estradiol, to augment the proestrus
surge of LH (22,25).
Administration of ovarian hormones to ovariectomized rats can mimic
the inhibitory and stimulatory actions seen during the estrous cycle.
Following ovariectomy, plasma LH rises and is secreted in a pulsatile
fashion (7,8), most probably a consequence of pulsatile LHRH release
(18).

Estradiol administration rapidly suppresses pulsatile LH release

in ovariectomized rats (9,10) thus providing a reliable model of estra
diol negative feedback effects.

Ovariectomized rats treated with estra

diol exhibit daily afternoon surges of LH (10,11) and progesterone
administration to such rats markedly stimulates the LH surge (12).
These stimulatory effects of the ovarian hormones have provided a model
of ovarian hormone positive feedback.
LHRH is the primary neural hormone regulating anterior pituitary LH
release (13).

LHRH cell bodies are concentrated in the diagonal band of

Broca, septal nucleus, and preoptic area (14,15) and project fibers to
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the median eminence that terminate on blood vessels of the portal system
of the pituitary (16,17).
LHRH appears to undergo fluctuations in rates of release during the
course of the estrous cycle (18) with greatest amounts of LHRH released
on proestrus (18,19).

In fact, LHRH release during proestrus has

recently been observed to of biphasic (18), with, an initial "priming"
pulse followed 2-3 hours later (1600— 1730 hours) by a much larger
secretion of LHRH.

This priming action of LHRH significantly enhances

the responsiveness of pituitary gonadotropes.

Thus, a smaller quantity

of LHRH may be required to initiate the LH surge (4,20) and LHRH release
is then coordinated with enhanced pituitary responsiveness (4,20).
LHRH release appears to be responsive to changes in ovarian hormone
concentrations during the estrous cycle.

Estradiol increases LHRH

release, both in vivo and in vitro (46,58).

In addition, progesterone

appears to have positive effects on LHRH synthesis and release (53,54,
55).
After release of LHRH into the pituitary portal system, LHRH interbinds to specific, high affinity membrane receptors to stimulate LH
release from anterior pituitary gonadotroph cells (225).

Ovarian hor

mone manipulation of LHRH may account, at lease in part, for the effects
of these hormones on LH release.

In support of this, the increase in

plasma LH levels observed after ovariectomy may be the result of an
enhanced output of LHRH into the portal system (26,27).

Moreover, the

administration of estradiol, which suppresses pituitary LH secretion,

also depresses levels of LHRH In portal plasma of ovariectomized rats
(26).
C.

Locus of Action of Ovarian Hormones in Regulation of LH secretion:
1.

Sites of negative feedback

The inhibitiory effects of estradiol on LH release are believed to
occur in both the pituitary and the brain, especially the medial basal
hypothalamus (MBH) (5).

Results from several lines of investigation

support the MBH as a site of estradiol's negative feedback: (1) estrogen
and/or progesterone bind to and are taken up by diencephalic cells,
including cells in the MBH (38), (2) implants of estradiol into the MBH
depress LH release (27,32), (3) MBH lesions block estrogen's inhibition
of LH in ovariectomized female rats (30), (4-) electrical stimulation of
the MBH depresses episodic LH release (31), and (5) damage to the MBH
from bilateral knife cuts suppresses pulsatile LH release (33).

These

observations suggest, therefore, that at least a part of estradiol's
inhibitory effects on LH release may occur in the MBH.
Although the importance of progesterone in providing tonic inhibi
tion of LH release during the estrous cycle has been established (22),
the site of progesterone's inhibitory effects is not clear.

Implants of

progesterone into the MBH (29) or peripheral administration of the hor
mone (36) causes inhibition of LH release.
Estradiol appears to also exert part of its negative feedback
effect on the pituitary gland.

The response of the pituitary gland to

release LH following LHRH administration is acutely enhanced by ovariec-
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tomy (33).

Moreover, estradiol reduces pituitary responsiveness to LHRH

in ovariectomized rats (37,39).
In contrast to a report of enhanced LHRH neurosecretion accompany
ing the post-ovariectomy increase in LH (26), other investigators (18,
40) have failed to demonstrate any increase in portal plasma LHRH levels
after ovariectomy.

These results would suggest that estradiol produces

its inhibitory effects on LH by acting on the pituitary gland.

In

further support of the anterior pituitary as the primary site of estra
diol's negative feedback effects, a recent report (41) observed that a
dose of estradiol that inhibits LH release, stimulates estrogen receptor
translocation in the pituitary gland but not in the MBH.

These results

suggest that estradiol exerts its inhibitory effects on LH secretion by
acting in the brain but perhaps mainly in the anterior pituitary.
2.

Sites of positive feedback

The majority of experimental evidence supports the concept that the
stimulatory effects of estradiol on LH release are exerted both in the
brain and at the level of the pituitary gland (5).

Within the brain,

the preoptic area (POA) appears to be the most sensitive area to estra
diol's effects.

Estradiol is taken up by neurons in the POA (38) and

electrochemical excitation of (42) or implantation of estradiol into
(43,44) the POA stimulates LH release.

In addition, damage to the POA

by knife cuts reduces gonadotropin secretion (45).

Estradiol's stimula

tory effects on LH secretion may be due to stimulation of LHRH release
(46).

LHRH levels in the portal blood are enhanced on the afternoon of

proestrous (18,19) and this has been attributed to an effect of
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increased estradiol concentrations (46).

Moreover, estradiol stimulates

the release of LHRH in vitro from the MBH of ovariectomized rats (58).
A portion of estradiol's positive feedback effects may occur in the
pituitary gland (5).

Estrogen increases the responsiveness of the pitu

itary to LHRH after pituitary stalk section (47) and also increases res
ponsiveness of pituitary cells to LHRH in vitro (48).

However, the pos

sibility that the enhanced pituitary responsiveness is due to increasd
LHRH release and to augmented "priming" actions of LHRH can not be
excluded (26).
The stimulatory effects of progesterone may also occur in the brain
or pituitary.

Progesterone (probably in combination with estradiol)

stimulates LH secretion on the afternoon of proestrous (12,52).
Implants of progesterone into the MBH at 1000 hours on proestrous leads
to ovulation (51).

Administration of progesterone to ovariectomized

rats primed with estradiol increases the concentration of LHRH in the
MBH (53) and enhances the secretion of LHRH into the pituitary portal
system (54).

In addition, in estradiol--primed rats, progesterone

stimulates the release of LHRH both in vivo and in vitro (55,56).
Stimulatory effects of progesterone have also been demonstrated in
the POA.

Implantation of progesterone into the POA-anterior hypothala

mic area (226) elevates LH release in estrogen-primed, ovariectomized
rats.

Thus, progesterone appears to act in both the MBH and POA to

induce LH release.

Progesterone may also produce part of its stimula

tory effects on LH release by an action on the anterior pituitary gland
(5).

Progesterone enhances the responsiveness of the pituitary gland to
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LHRH (49,50).

However, the possibility can not be excluded that

enhanced pituitary responsiveness by progesterone to LHRH may be due to
increased LHRH release or augmented "priming" action of LHRH (26).
D.

Mechanism of Action of Ovarian Hormones
The mechanism of action of the ovarian hormones in producing their

feedback effects may be by direct interaction with nerve cell membranes
or by indirect actions at the level of the genome (59).

An indirect

mechanism of action of the ovarian steroids at the genomic level would
involve an interaction of the hormone with its receptor to alter RNA
synthesis and gene transcription (60).

Steroid hormones diffuse freely

into cells and are retained due to binding to receptor sites found only
in target cells (61).

This hormone-receptor complex then migrates to

the nucleus and binds there to nuclear acceptor sites (61).

The nuclear

acceptor sites are composed largely of chromatin, a mixture of DNA and
DNA-nonhistone protein complexes (61,62).

After binding to the nuclear

acceptor complex, the hormone is capable of altering RNA synthesis
(61,62).
The possibility that the ovarian hormones may alter genomic func
tion to produce their feedback effects is supported by observations that
these hormones affect the levels of specific enzyme and neurotransmitter
receptor proteins in the brain (63).

Estrogen receptors have been

demonstrated in the brain, especially concentrated in areas thought to
be involved in the regulation of LH secretion, e.g. the POA and MBH (38,
64).

Estrogen treatment can alter the levels of enzymes, such as cho

line acetyltransferase, acetylcholinesterase, glutamic acid decarboxy
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lase, tyrosine hydroxylase, and type A monoamine oxidase that regulate
neurotransmitter biosynthesis and degradation (59,63).

Estrogen has

also been shown to be able to induce progestin receptors in the POA (65)
and to increase the number of muscarinic cholinergic, B— adrenergic, and
serotonin type 1 receptors (63).

However, whether these effects of

estradiol are the result of genomic action and what role they play in
ovarian hormone feedback remains undetermined.
Other lines of evidence do lend support to the concept that a por
tion of ovarian hormone feedback action is at the genomic level.

The

effect of estradiol in inducing hypothalamic progestin receptors is
blocked by the protein synthesis inhibitor, anisomycin (63).

Moreover,

microapplication of anisomycin to ventral medial hypothalamus prevents
the activation of feminine sexual behavior induced by estradiol and pro
gesterone (65).

Estradiol activated RNA polymerase II in the hypothala

mus (60) and recent evidence indicates that estradiol--induced receptor
translocation in the pituitary and POA can be correlated to estradiol's
negative and positive feedback effects, respectively (41).
Estradiol may produce a portion or all of its feedback actions by
mechanisms other than classical receptor mechanisms.

Estradiol could

have direct effects on all membranes of LHRH neurons, catecholamine neu
rons, or pituitary gonadotrope cells and thereby regulate gonadotropin
secretion.

In support of this concept, estradiol induces Ca++ dependent

action potentials (66) and stimulates prolactin release (67) from cloned
pituitary cells.

Estradiol also stereospecifically hyperpolarizes POA

and MBH neurons by a direct membrane effect (68) and although the iden

9
tity of the neurotransmitter/neuropeptide contained in these neurons is
unknown, some of the neurons may contain LHRH (69).

Thus, estradiol

may produce its negative and positive feedback effects by either direct
effects in the brain or on the pituitary and/or indirect effects
mediated at a genomic level in these tissues.
E.

Role of Catecholamines in Regulation of LH Secretion
1.

General considerations

The catecholamines, dopamine, norepinephrine, and epinephrine are
synthesized from the amino acid tyrosine (70).

An active transport

mechanism transports tyrosine into the nerve terminal where the enzyme
tyrosine hydroxylase converts tyrosine to 3,4-— dihydroxyphenylalanine
(DOPA), the formation of which appears to be the rate limiting step in
catecholamine biosynthesis (71).

Tyrosine hydroxylase is a stereo

specific enzyme that requires a tetrahydropterine cofactor, in addition
to Fe++ and molecular 02 (70).

Alpha methyl--p--tyrosine, a competitive

inhibitor of tyrosine, is an effective inhibitor of this enzymatic
step.

A carboxyl group is removed from DOPA by the enzyme L-aromatic

amino acid decarboxylase, a non-specific enzyme requiring pyridoxal
phosphate (72), to form dopamine (DA).

DA is then transported, via a

Mg*+--ATP dependent process, into storage granules where it is stored
until conversion to norepinephrine (NE) (70).

DA is converted to NE by

the enzyme dopamine--B--hydroxylase (DBH) in an enzymatic process
requiring ascorbate and molecular oxygen.

DBH is a Cu++--containing

protein and copper chelating agents, e.g. FLA--63, are very effective
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inhibitors of this enzyme (70).

NE in the brain and adrenal medulla is

subsequently methylated by the enzyme phenylethanolamine--N--methyl
transferase (PNMT) to form epinephrine (EPI) in a reaction that uses Sadenosyl methionine as a methyl donor (73).

Several competitive inhibi

tors of PNMT including SK & F 64-139 and LY 78335 effectively inhibit EPI
synthesis and consequently lower EPI concentrations in the brain tissue
(74).
Following calcium--dependent release of either DA, NE, or EPI into
the synaptic cleft, the catecholamine acts on specific receptors located
on the effector cells.

Multiple receptors on which the catecholamines

act to produce their effects have been implicated for DA (D1 & D2) (75),
and NE and EPI (alpha 1, alpha 2, beta 1, beta 2), (76,77).

In addition

to these post--synaptic receptors, abundant evidence indicates the pre
sence of pre— synaptic receptors on catecholamine neurons that are
involved in regulation of neurotransmitter release (78).
Pre--synaptic receptors involved in regulation of neurotransmitter
release could include autoreceptors for the transmitter the neuron
released, in addition to receptors for NE, DA, EPI, serotonin, angioten
sin II, opioid peptides, acetylcholine, and prostaglandins (78).
The majority of NE, DA, or EPI released by nerve impulses is taken
back up into the nerve terminals by an active re--uptake process (79).
After re--uptake, catecholamines are degraded by two main enzymes, mono
amine oxidase (MAO) and catechol--methyltransferase (COMT).

Most of the

release of NE and EPI that escapes re-uptake is metabolized by COMT to
noremetanephrine and metanephrine, respectively (80).

Normetanephrine
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and metanephrine are converted by MAO to 3-methoxy-4-hydroxy-mandelic
acid (VMA), the major metabolite of catecholamines excreted in the urine
(70).

MAO and COMT, in addition to aldehyde reductase and dehydrogen

ase, converts NE to 3,4 dihydroxyphenylglycol, 3,4 dihydroxyphenylethylglycol, and 3-methoxy-4-hydroxy-phenylglycol (80).

DA also be converted

to 3,4-dihydroxyphenylacetic acid by MAO and aldehyde dehydrogenase be
fore being metylated by COMT to homovanillic acid (80).
The anatomical pathways of the catecholaminergic systems have been
extensively analyzed (81,82).

The noradrenergic system can be divided

into the dorsal tegmental pathway and the ventral tegmental pathway
(81).

The dorsal tegmental pathway arises from cell bodies of the locus

coeruleus (A6) (83) and projects primarily to the cerebral cortex,
hippocampus, hypothalamus, and cerebellum (81).

The ventral tegmental

pathway originates from A1,2,5,7 cell groups and innervates the
hypothalamus, thalamus, brainstem (81).
The adrenergic systems have been termed C1 and C2 and are similar
in many respects to cell groups A1 and A2 of the noradrenergic system.
Cell bodies of the adrenergic system appear to originate in the lateral
reticular nucleus (C1) and rostral medulla near the nucleus of the soli
tary tract (C2) (84).

Adrenergic projections have been observed in the

hypothalamus, thalamus, lower brainstem and intermediolateral cell
column of the spinal cord (84).
The dopaminergic systems of the brain can be divided into nigrostriatal, mesocortical, incertohypothalamic, periventricular, and tuberohypophyseal pathways.

The dopaminergic pathways provide DA to a variety
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of brain regions including the striatum, isocortex, allocortex, median
eminence and pituitary, septum, and dorsal and pariventricular
hypothalamic areas (82).
2.

Catecholamine Involvement in Episodic LH release

Available evidence indicates an inhibitory role for DA in episodic
LH secretion in the rat (85).

DA and DA agonists such as apomorphine

reduce LH release in ovariectomized rats (86,87,88).

The inability of

DA antagonists such as pimozide to affect LH release (87) has prompted
the suggestion that DA is not a major regulator of steady state pulsa
tile LH release (85).
In the rat, there appears to be a dual noradrenergic regulation of
pulsatile LH release, i.e. both inhibitory and excitatory components
have been described (85).

Infusion of NE or clonidine intraventrtcu-

iarly to ovariectomized rats suppresses episodic LH release (88,89).
However, an excitatory noradrenergic system may also participate in
regulating pulsatile LH release.

Reduction of hypothalamic NE levels

(86,87) or blockade of NE receptors (90) inhibits episodic LH release.
The physiological significance of such a dual system in regulating epi
sodic LH release in ovariectomized rats remains to be established (85,
91).

However, administration of estradiol decreases the turnover of NE

in the POA and MBH of ovariectomized rats, concomitant with a reduction
of circulating LH levels (105,106,110).

Thus, disturbance of a stimu

latory noradrenergic influence on LHRH release may produce estradiol's
inhibitory effect on LH release.

EPI appears to play little role in
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regulating episodic LH release (92).

Inhibition of EPI synthesis (92)

or infusion of the catecholamine intraventricularly (88) were without
effect on LH release suggesting that EPI is not involved in controlling
pulsatile LH release.
3.

Catecholamine Involvement in the Preovulatory or ovarian

Hormone--Induced LH surge
Catecholamines were initially implicated in the regulation of LH
release following observations that dibenamine, an adrenergic blocking
agent, suppressed copulation--induced ovulation (93).

Subsequent stud

ies demonstrated that dibenamine and reserpine, depletors of monoamines
from nerve terminals, blocked ovulation in normal cycling rats (94,95).
Reserpine's inhibitory effect could be reversed by administering MAO
inhibitors to prevent catecholamine metabolism (96).
Research over the last dozen years has solidified the involvement
of catecholamines in the regulation of gonadotropin secretion and sug
gested that NE is the primary mediator of ovarian hormone positive feed
back effects.

Interruption of NE synthesis with inhibitors of tyrosine

hydroxylase or DBH inhibited preovulatory LH surges (97) and surges of
LH induced by treatment of ovariectomized rats with estradiol and pro
gesterone (98).

The aforementioned inhibitory effects are reversed by

injections of dihydoxyphenylserine (DOPS), a NE precursor (98).

Preven

tion of noradrenergic effects by receptor blockade with phenoxybenzamine
or haloperidol also abolishes proestrus or ovarian hormone-induced LH
surges (98,99).

In addition, infusion of NE intraventricularly to pro-

estrous rats or ovariectomized rats primed with ovarian hormones
stimulates LH release (100,101) and NE is capable of promoting LHRH
release both in vivo (102) and in vitro (103).

More recently, ovarian

hormone treatments that produce an LH surge have been shown to enhance
the turnover of NE in the P0A and MBH of ovariectomized rats
(104,103,106).

Taken together, these findings provide support for the

hypothesis that an increased noradrenergic neurotransmission underlies
the stimulatory feedback effects of estradiol and progesterone on LHRH
and LH release.
Whereas a stimulatory role for NE in gonadotropin secretion seems
clear, the role of DA continues to be controversial.

DA and the DA

agonist apomorphine elevate LH concentrations when injected intraventricularly to cycling rats or ovarian hormone primed ovarectomized rats
(102, 107) and elicits LHRH release from median eminence fragments in
vitro (103).

Moreover, DA turnover has been observed to be elevated on

the afternoon of proestrus in the median eminence and arcuate nucleus
(108).

In contrast, DA and apomorphine reduce LH release in ovariecto

mized rats (83,88) or do not affect LH release under a variety of endo
crinological manipulations (88,100,1109).

The inconsistency of effects

found with DA has resulted in the failure to define a specific role, if
any, for this catecholamine in the regulation of gonadotropin release,
using the female rat as a model.
In contrast to NE, the role of central EPI systems in mediating
ovarian hormone feedback had been, until recently, overlooked.

Although

EPI systems appear to play little role in episodic LH release (88,92),
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several early reports revealed a possible stimulatory role in cycling
animals.

Intraventricular infusion of EPI elicits ovulation in estro

gen-primed rabbits (111) and proestrus pentobarbital-treated rats
(100).

In addition, EPI stimulates LH release after intraventricular

administration in ovariectomized rats primed with ovarian hormones (88,
101).

However, the low concentration of EPI compared to NE in the brain

(112) and the non-specificity of drugs available to differentiate adre
nergic effects from noradrenergic ones, prompted many investigators to
discount the role of EPI in controlling LH secretion.

In recent years,

the development of specific PNMT inhibitors (113,114) provided a needed
tool to define the involvement of EPI in ovarian hormone feedback.
Recent studies have demonstrated that selective inhibition of EPI
synthesis prevents preovulatory (116) and ovarian hormone--induced LH
surges (92,115).

Thus, both NE and EPI may be involved in the stimula

tory (positive) feedback effects of the ovarian hormones.

A major goal

of this research is to define the possible sites and mechanisms of
action of the ovarian hormones on EPI systems and the relationship of
these effects to ovarian hormone positive feedback.
4.

Local Modulation of Catecholamine Activity

The mechanisms by which the ovarian hormones alter catecholamine
activity to produce their stimulatory effects on gonadotropin secretion
are not well understood.

Although estradiol and progesterone may affect

catecholamine systems directly, several lines of evidence suggest that
the ovarian hormone— catecholamine interaction may be indirect (117).
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Estradiol and progesterone are taken up avidly in areas that receive
ascending catecholaminergic innervation (38,614,118) and it is in these
areas that the ovarian hormones seem to produce their effects on cate
cholamine turnover and on LH release.

In addition, the changes in

catecholamine turnover produced by estradiol and progesterone are
usually confined to a few discrete regions (108,110).

These

observations suggest that the ovarian hormones may effect the activity
of intrahypothalamic systems that could exert discrete control over
catecholamine release.
F.

Role of Neuromodulatory Systems in Ovarian Hormone Feedback
1.

The Endogenous Opioid Peptides--general considerations

The endogenous opioid peptides can be separated into three main
groups:

the enkephalins, peptides similar to beta-endorphin, and pep

tides related to dynorphin (120).
the three groups of peptides.

Different genes appear to code for

Pre--proopiomelanocortin (POMC) is an in

active prohormone of which enzymatic cleavage produces several hormones
including B--endophin, ACTH, and melanocyte stimulating hormone (121).
Preproenkephalin is the 263 amino acid precursor for the enkephalin pep
tides containing four copies of Met--enkephalin, one Leu--enkephalin
peptide sequence, and two sequences of C-terminaily extended peptides,
Met5— enkephalyl--Arg--Gly and Met5— enkephalyl--Arg--Phe (122,123).
Pre— prodynorphin containing 236 amino acids, is the precursor for
dynorphin A, dynorphin B, and alpha--neo--endorphin (124).
The central distribution of the opioid peptides has only recently
been revealed.

The distribution of the enkephalins, presently the best
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characterized of the opioid peptides, includes cell bodies in the (1)
telencephalon (caudate nucleus, nucleus accumbens, nucleus interstitialis of the stria terminalis (NIST), amygdala) with projections to, most
importantly, the globus pallidus, but also to the amygdala and NIST; (2)
the diencephalon, mainly the hypothalamus, with projections to areas
including the median eminence, the supraoptic nucleus, and neurohypo
physis; (3) the brain stem and spinal cord, with cell bodies and fibers
in a variety of areas including substantial grisea centralis, inter
peduncular nucleus, dorsal
tegmental nucleus, raphe area, nucleus of the solitary tract, dorsal
horn and intermediolateral horn (125).
Cell bodies containing beta— endorphin appear to be concentrated
almost exclusively in the arcuate nucleus of the MBH (126).

Fibers

originating from this area extend to the lateral septum and nucleus
accumbens and are abundant in many nuclei of the hypothalamus (126).
Other fibers project prominently to such brain stem sites as the peri
aqueductal grey, the nucleus of the solitary tract, and the locus
coeruleus (126).
The distribution of dynorphin and related peptides is less well
established.

Dynorphin A has been found in substantial amounts in the

posterior pituitary (127) and seems to be concentrated in supraoptic and
paraventricular nuclei (128) of the hypothalamus and the dorsal horn of
the spinal cord (129).
The opioid peptides produce their biological effects through inter
actions with a heterogenous population of receptors (130).

The opioid
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receptors, termed mu, delta, sigma, kappa and epsilon, appear to bind
different opiate and opioid peptides with varying degrees of specificity
(131).

Beta--endorphin seems to have equal affinity for mu and delta

subtypes with little specificity for kappa receptors (131).

The enke

phalins, however, have much greater affinity for delta sites than mu,
with little specificity for kappa sites.

Recent evidence indicates that

the dynorphin peptides may be the endogenous ligand for the kappa recep
tor subtype (132).
2.

Endogenous Opioid Peptides and Ovarian Hormone Positive

Feedback
The endogenous opioid neuropeptides, such as the dynorphins, betaendorphin, or met— enkephalin, are possibly involved in ovarian hormone
feedback as neuromodulators of catecholamine activity for several
reasons.

First, neurons containing these peptides are located in estra

diol target areas, including the POA and MBH (128,133,134).

In fact, a

recent study observed that beta— endorphin neurons in the arcuate nu
cleus also accumulate estrogen (146) suggesting that these neurons are
sites of estradiol action.

The POA and MBH are also densely innervated

by catecholamines (81,82).

Secondly, the alkaloid opiate agonist,

morphine, and the endogenous opioid neuropeptides reduce both central
and peripheral NE release (135,136), most likely an action due to
activation of inhibitory presynaptic receptors (137).

Thirdly, morphine

and the opioid peptides have profound neuroendocrine effects.

Morphine

and the opioid peptides depress the proestrous surge of LHRH and LH
(138), block ovulation (139,140), and prevent in ovariectomized rats the

surge of LH produced by treatment with ovarian hormones (141).

In

addition, the specific opioid receptor antagonist, naloxone, blocks
these effects (138, H O , 14-1,142) and elevates LH when administered alone
( H I ,H 3 , 144,143).

Moreover, morphine suppresses NE turnover enhanced

by ovarian hormone priming (H).

Recent pharmacological evidence sug

gests that this effect of naloxone to increase LH release may be due to
activation of the stimulatory NE and/or EPI systems ( H 1 , H 5 ) .

Thus, it

is conceivable that ovarian hormones may alter the activity of an endo
genous opioid neuropeptide system that regulates catecholaminergic
neurotransmission.

A second major focus of the present research will

investigate the role of endogenous opioid peptides in modulating ovarian
hormone effects on NE and EPI activity.

3.

Gamma Aminobutyric Acid (GABA)--General Considerations

Gamma-aminobutyric acid (GABA) is the primary inhibitory neuro
transmitter in the brain (H8).

GABA acid is synthesized in the brain

from glutamic acid catalyzed by the enzyme glutamic acid decarboxylase
(GAD), with the coenzyme pyridoxal phosphate required ( H 8 , H 9 ) .

GABA

Acid is further metabolized to succinic semialdehyde by the enzyme GABA:
2— oxoglutamate aminotransferase (GABA— T), in a reaction also requiring
pyrodoxal phosphate (H9).

Succinic semialdehyde is converted to suc

cinic acid by the enzyme succinic semialdehyde dehydrogenase.
GABA acid has been reported to have a specific distribution in mam
malian brain (130,151,152).

The distribution of GABA, determined by

both biochemical and immunohistochemical methods, seems to be highest in
hypothalamic (peri--and para ventricular, arcuate, preoptic, and
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anterior hypothalamic) nuclei, as well as the substantia nigra and glo
bus pallidus (150,151,152).
Electrophysiological analysis of GABA effects has revealed two
different mechanisms of actions (149).

GABA receptor activation can

lead to hyperpolarization of the target neuron, a result due to an
enhanced chloride ion inhibition, GABA is also capable of
pre--synaptically inhibiting nerve terminals by depolarization (149), an
effect associated with an increased C1- ion conductance out of the
neuron.
Results from biochemical, electrophysiological, and pharmacological
studies have demonstrated the heterogeneity of central GABA receptors
(154).

Classical GABA A receptors appear to be linked to choride ion

channels as stimulation of the GABA A receptor increases conductance
leading to hyperpolarization (153).

In contrast, GABA B receptors are

not associated with chloride ion channels (154) but more possibly linked
to voltage sensitive calcium channels in which activation depresses
calcium conductance.

GABA A and GABA B receptors may also be classified

by pharmacological properties.

Although GABA is a potent agonist at

both sites, muscimol, isoguvacine, and Thip are active only at GABA A
sites and inactive, or only weakly active at GABA B sites (154,158).
Para--chloro--phenyl GABA (baclofen) is a potent agonist at GABA
sites and is inactive at GABA A receptors (159,160,161).
also display differential sensitivity to antagonists.

B

GABA receptors

GABA A sites are

antagonized by bicuculline (162) whereas GABA B receptors are insensi
tive to bicuculline antagonism (159,160).

Although a pure GABA B anta
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gonist has not been identified, 5--aminovalerate may have some, albeit
weak, GABA B antagonistic effects (163,164).
4.

GABA and Ovarian Hormone Feedback

GABA is also a candidate for a neuromodulatory role in ovarian hor
mone feedback.

The reasons for suspecting GABA are very similar to ones

for the endogenous opioid neuropeptides.

GABA is densely concentrated

in many hypothalamic regions, especially the medial basal area (150,
151,152) were GABAergic fibers are mixed with monoaminergic and LHRH
systems (165,166).

Furthermore, GABA and GABA agonists, such as

baclofen, reduce the evoked release of 3H--NE, both centrally and
peripherally (159,163,167,168).

However, the evidence is somewhat

conflicting on the influence of GABA on LH release.

For example, GABA

stimulates LH release in anesthetized male rats (169) but is without
effect in unanesthetized male rats (170).

Intraventricular

administration of GABA increases LH levels in ovariectomized and
ovariectomized, ovarian hormone primed (171,172).

However, more recent

studies have been able to demonstrate an inhibitory influence of GABA
and the GABA agonist, muscimol, on LH release (173,174,175).

In these

studies, intraventricular administration of GABA or muscimol reduces LH
and suppresses POA NE turnover in ovariectomized or ovariectomized,
ovarian hormone--primed female rats (173,174,175).

Moreover, muscimol

implanted locally into the POA decreases LH (175), and an estradiol
treatment that reduced LH levels stimulated GABA turnover in the POA
(174).

Interestingly, a recent report noted that GABAergic neurons in

the POA can accumulate delete estradiol (176) suggesting that estradiol
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may affect GABA transmission in the PDA.

Thus, it has been proposed

that estradiol may produce its negative feedback effects by enhancing
POA GABA turnover which would, in turn, suppress stimulatory
noradrenergic inputs to LHRH neurons (173,174,175).
Other lines of evidence also support an ovarian hormone--GABA
interaction.

The activity enzyme mediating GABA synthesis, GAD, is

increased to estradiol treatment (177,178) and intraventricular
injection of GABA blocks ovulation in immature rats (179).

Evidence

presently available strongly suggests a role for GABAergic neurons in
ovarian hormone negative feed-back.

A third major portion of the

present research will examine the role of GABAergic neurons in
modulating the stimulatory effects of the ovarian hormones on LH and on
hypothalamic catecholamines.

CHAPTER II
STATEMENT OF THE PROBLEM

This research tests the interrelated hypotheses that the ovarian
hormones produce their positive feedback effects on LH secretion through
activation of noradrenergic and adrenergic systems in specific hypotha
lamic regions.

Furthermore, the ovarian hormones may alter the activity

of opioid neuropeptide and GABA systems to produce these alterations in
catecholamine neurotransmission and gonadotropin secretion.
The specific objectives of these studies are to:
1)

test whether selective catecholamine synthesis inhibitors pre

vent the ovarian hormone--induced accumulation and decline of LHRH in
the median eminence.
2)

examine whether an ovarian hormone regimen that elicits an LH

surge enhances the activity of NE and EPI neurons in discrete regions of
the hypothalamus.
3)

test whether the opiate antagonist, naloxone, enhances the

activity of NE and EPI neurons in discrete regions of the hypothalamus.
4)

test whether the opiate agonist, morphine, which blocks the LH

surge, depresses the activity of NE and EPI neurons in discrete regions
of the hypothalamus.
5)

investigate the effects of the GABA A agonist, muscimol, the

GABA B agonist, baclofen, and the GABA antagonist, bicuculline and
5--aminovaleric acid on LH release.
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6)

test whether the GABA agonists depress the activity of NE and

EPI neurons in discrete regions of the hypothalamus.
7)

test the effects of GABA agonists on the rise of LHRH induced

by progesterone.
8)a)

examine whether the GABA agonist, baclofen, reverses the

enhancement of LH release and catecholamine activity produced by
naloxone.
b)

test whether the opiate antagonist, nalmefene, prevents the

blockade of the LH surge produced by baclofen.

CHAPTER III
MATERIALS AND METHODS
A.

Routine Animal Care
Adult, Sprague--Dawley albino female rats (Harlan Industries, Inc.

Indianapolis) were used in the experiments, approximately 60 days of age
at the beginning of each experiment.

Animals were housed in groups of

five and maintained on a 14 h light:10 h dark schedule (lights on 0500-1900) with water and food ad libitum.

All rats were ovariectomized and

allowed two--three weeks recovery.
B.

Brain Microdissection
The microdissection technique is based on that described by Palko-

vits (180).

After decapitation, brains are removed quickly and frozen

on powdered dry ice.

Three hundred micrometer thick coronal sections

were cut at -4- degrees C on a microtome cryostat.
frozen onto microscope slides.

Brain sections were

Individual brain nuclei were then re

moved from the sections with stainless steel cannulae while viewed with
a dissecting stereomicroscope.

Generally, the appearance of brain ven

tricles, tracts, and recognizable nuclei were relied upon to guide the
dissection.

The dissected tissue was placed into the appropriate medium

(0.1 N HClOt* for catecholamines; 1 N HC1 for LHRH) and homogenized by
sonication.

Aliquots were removed for protein determination (181).

supernatent was then used for neurochemical analysis.
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C.

Regional dissection o_f the hypothalamus
After decapitation, brains were removed rapidly and frozen on

powdered dry ice.

Two discrete brain regions were then dissected:

medial preoptic— anterior hypothalamic area (POA) and 2)
hypothalamus (MBH).

1)

medial basal

The POA fragment is bordered by the optic chiasm

rostrally and supraoptic commissures caudally, the anterior commissure
dorsally, and extendes approximately 1 mm lateral to the midline on
either side.

The MBH fragment was bounded by the rostral--caudal extent

of the median eminence, the infundibular sulcus laterally, and extended
approximately 1 mm dorsally.

These areas were weighed, homogenized in 1

ml of cold 0.1 N HClOt*, and centrifuged at 10,000 rpm for 30 minutes.
Aliquots of sixty microliters were assayed for catecholamines with a
sensitive radioenzymatic assay (182,183,184).
D.

The alpha--Methyl Tyrosine Method
As an index of catecholaminergic activity, the studies measured the

depletion of hypothalamic catecholamines one hour after administration
of the catecholamine synthesis inhibitor alpha-methyl tyrosine (aMT).
The extent of catechoamine depletion after aMT administration depends
largely upon the rate of nerve impulse flow (183).

For example, after

mid-thoracic spinal transection, the ability of aMT to reduce NE concen
trations caudal to the transection is lost, suggesting that intact
neuronal activity is essential for aMT to reduce NE levels (185).

This

method has since been used to study the effects of drugs on catechola
mine function.

A more pronounced decline after aMT indicates an
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"increased release" of transmitterr from nerve terminals, while a
smaller decline reflects a relatively low state of activity.

The aMT

method, like all non-steady state methods, carries the limitation that
synthesis blockade, with subsequent increases in transmitter levels, may
affect the normal activity of the system (186).

Although the method is

limited to a lesser extent in that it may not provide a true turnover
rate per se (186), any differences between two groups in the degree of
depletion reflect differences in turnover (185).

Thus, this approach is

most appropriate for comparing the effects of different experimental
conditions on catecholamine function.
E.

Analytical Methods
1.

Catecholamines:

Concentrations of catecholamines were deter

mined by radioenzymatic assay (182,183).

This assay used a partially

purified preparation of catechol-O-methyltransferase to induce catecho
lamine methylation with radiolabeled S-adenosyl-L-methionine acting as
the methyl donor.

The resulting methylated catecholamines were purified

by solvent extraction and isolated by thin layer chromatography.

The

O-methylated compounds were then counted by liquid scintillation (18*0.
The sensitivity of the assay is approximately equal to 5 pg for the
three catecholamines.
2.

Radioimmunoassay:

Luteinizing Hormone.

In each study, trunk blood was collected

after decapitation and centrifuged at 2000 rpm for 20 minutes.
was separated and stored at -85 degrees C.

Serum

LH and prolactin were
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measured by double antibody radioimmunoassays, using NIADDK/NICHD Natio
nal Hormone Pituitary Program reagents and procedures.
transformation was used for data calculation (178).

Log logit data

The inter--and

intraassay coefficients of variation for LH were 13.5% and 6%, respec
tively.
LH--Releasing Hormone.

LHRH was measured by the double antibody

radioimmunoassay of Nett, et. al. (188), using the R— 4-2 antiserum.
Synthetic LHRH (Peninsula Laboratories) was used for reference standard
and for iodination.

Monoiodinated LHRH was prepared by a modification

of the chloramine T method (189).

Intraassay coefficients of variation

ranged from 1% to 7%, and the sensitivity of the assay was approximately
0.5 pg/tube.
F.

Hormone and Drug Treatments

Experiment 1:

Effects of PNMT and DBH inhibitors on the LH and LHRH

surges induced by ovarian hormones
In this study, as in other studies of the project that investigated
the positive feedback effects of the ovarian hormones, stimulatory
sequential ovarian hormone priming was used.

In each study, ovariecto-

mized female rats received sc injections of estradiol benzoate (EB; 50
micrograms at 1000 h) followed by progesterone (P; 2.5 mg) 48 h later.
Henceforth this shall be simply referred to as EB— P priming.
In each study of experiment 1, the animals received the EB--P prim
ing.

Beginning 1 h before the progesterone injections, animals received

ip injections of one of the following 1)

the EPI synthesis inhibitor
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SKF 64139 (30 mg/kg), 2)

the DBH inhibitor FLA-63 (40 mg/kg), or 3)

the EPI synthesis inhibitor LY 78335 (50 mg/kg).

The EPI synthesis

inhibitors were dissolved in saline while FLA-63 was dissolved in 1 N
HC1, buffered to pH 6.8 and diluted in saline.

In each experiment,

appropriate saline vehicle controls were conducted simultaneously.
Selected animals were killed by decapitation at various times after
progesterone treatment in order to encompass the changes in tissue LHRH
and plasma LH concentrations.

Plasma LH and median eminence LHRH were

measured by radioimmunoassay.

To varify the effectiveness of the

catecholamine synthesis inhibitors, concentrations of NE, EPI, and DA
were determined in the POA.
Experiment 2:

Effects of ovarian hormones on catecholamine activity in

the hypothalamus.
This study tested whether hypothalamic catecholamine neurons are
activated by an ovarian hormone treatment that induces an LH surge.
Ovariectomized rats received sequential oil or EB-P priming and were
sacrificed either 3h after progesterone (or oil) or 6h after proges
terone treatment.

The period 3 h after progesterone corresponds to the

approximate time during which LHRH levels are increased in the median
eminence.

The period 6 h after progesterone corresponds to the time of

the LH surge.

One hour before decapitation, half of the animals in each

group were given ip injections of saline, and half received the catecho
lamine synthesis inhibitor alpha-methyl tyrosine methyl ester HC1 (400
mg/kg base; aMT).

Concentrations of NE, EPI, and DA in the POA and MBH
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were determined by radioenzymatic assay.
Experiment 3:

Effects of naloxone on LH release and catecholamine turn

over in the POA and MBH of estradiol— primed rats.
This experiment was designed to test whether naloxone, an opiate
antagonist, mimics the effects of progesterone in increasing LH release
and catecholamine turnover in rats primed with estradiol.
experiment, rats were primed with EB at 1000h.

In this

Fifty hours later

(1200h), animals received ip injections of either saline vehicle or
naloxone HC1 (10 mg/kg) and were sacrificed 1 h later.

In order to

assess catecholamine activity, one half of the animals in each group
were given aMT (400 mg/kg) simultaneously with the naloxone or saline.
Plasma LH was determined by radioimmunoassay and catecholamine
concentrations in POA and MBH were measured with radioenzymatic assay.
Experiment 4:

Effects of morphine on LH release and on catecholamine

turnover in the POA and MBH of EB-P primed rats.
This experiment tested whether the opiate agonist, morphine which
blocks the LH surge, will also prevent the stimulation of catecholamine
turnover induced by estradiol and progesterone.
EB-P priming and were sacrificed 3 h later.

Animals received the

One hour prior to decapita

tion, groups of progesterone treated animals received either saline,
morphine HC1 (10 mg/kg), or morphine plus naloxone HC1 (3 mg/kg).
the same time, half of the animals in each group received aMT.

At

Doseages

of opiate drugs used in Experiments 3 and 4 were chosen on the basis of
those doses known to affect LH release.

Plasma LH was determined by
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radioimmunoassay and catecholamine concentrationsin POA and MBH were
measured with a radioenzymatic assay.
Experiment 3:

Effects of GABA agonists and antagonists on LH secretion

in ovariectomized and ovariectomlzed, ovarian hormone-primed rats.
The first study of Experiment 5 was designed to test the effects of
GABA agonists and antagonists on the surge of LH induced by the ovarian
hormones.

Animals received seguential oil or EB-P injections.

Concomi

tant with the progesterone injections, animals were given ip injections
of either saline vehicle, the barbiturate, phenobarbital (50 mg/kg), the
selective GABA B agonist, baclofen (10 mg/kg), or the GABA A agonist,
muscimol (2 mg/kg).

Additional animals in each group also received the

postsynaptic GABA A antagonist, bicuculline (1 mg/kg) or the putative
GABA B antagonist, 5 aminovaleric acid (10-150 mg/kg), simultaneously.
In order to ensure maximal duration of drug action, half of the animals
in each group received a second injection at 14-00 h of their respective
agonist or agonist plus antagonist.
A second study tested whether the GABA agonists, baclofen or musci
mol, directly affect the anterior pituitary gland.
stimulatory EB-P priming.

Rats were given the

Beginning with the progesterone injections,

the animals received simultaneous ip injections of either saline vehi
cle, baclofen (10 mg/kg), or muscimol (2 mg/kg).

Two hours after pro

gesterone (1200 h), animals received either saline vehicle or 100 ng
synthetic LHRH subcutaneously and were sacrificed 15 minutes later.
A third study was performed to examine the effects of the GABA ago
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nists on LH release In ovariectomized, hormonally untreated rats.

In

this experiment, ovariectomized rats received at 1200 h ip injections of
either saline vehicle, baclofen (10 or 20 mg/kg), or muscimol (2 mg/
kg).

Additional agonist treated animals were also given bicuculline

(1-4 mg/kg) simultaneously.
hour after drug treatment.
Experiment 6:

Animals were sacrificed by decapitation one
LH was determined by radioimmunoassay.

Effects of GABA agonists on catecholamine turnover in the

POA and MBH of rats treated with ovarian hormones.
Experiment 6 was designed to test whether GABA agonists alter hypo
thalamic catecholamine activity in rats pretreated with ovarian hormo
nes.

In this study, ovariectomized rats received the stimulatory EB-P

priming, and were sacrificed 3 h after progesterone.

Concomitant with

the progesterone injections, animals received ip injections of either
baclofen (10 mg/kg), muscimol (2 mg/kg), or saline vehicle.

To assess

effects on catecholamine activity, one hour before decapitation, half of
the animals in each group received aMT (400 mg/kg).

Plasma LH was

determined by radioimmunoassay and catecholamine concentrations in POA
and MBH were measured with a radioenzymatic assay.
Experiment 7;

Effects of <i GABA agonists on the median eminence

accumulation of LHRH induced by progesterone.
This study was designed to test whether the GABAg agonist, baclo
fen, can prevent the ovarian hormone stimulation of LHRH concentrations
in the median eminence.

Animals received the stimulatory EB-P priming.
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Concomitantly with the progesterone injections, animals received ip
injections of either baclofen (10 mg/kg), or saline vehicle.

Animals

were sacrificed either 1, 2, 3, 4, or 6 hours after progesterone in
order to encompass the changes in tissue LHRH and plasma LH concentra
tions.

Animals sacrificed 6 h after progesterone received a second

injection of their respective drug or saline treatment at 14-00 h.

LHRH

and LH were measured by radioimmunoassay.
Experiment 8at

Effects of baclofen on naloxone's enhancement of LH

release and catecholamine activity in estradiol-primed rats.
Experiment 8b:

Effects of nalmefene on the blockade of the LH surge

produced by baclofen.
Two studies examined the interactions between GABA agonists and
opiate antagonists and their relationship to LH release and catechola
mine activity.
In the first study, ovariectomized rats received sc injections of
EB followed fifty hours later (1200 h) by ip injections of either saline
vehicle or naloxone HC1 (10 mg/kg).

Simultaneously, one half of the

animals in each group received saline or aMT and were sacrificed one
hour later.

In order to assess the effects of baclofen on naloxone-

induced catecholamine turnover, 30 minutes before naloxone, EB primed
animals were given either baclofen or saline.
A second experiment was designed to test whether the opiate anta
gonist, nalmefene, prevents the blockade of the EB-P priming effect.

At
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the time of the progesterone administration, animals received ip
injections of either saline, baclofen (10 mg/kg), nalmefene (10 mg/kg),
or baclofenplus nalmefene.

To assure maximal duration of drug action,

all animals received at 1400 h a second injection of their respective
drug or drug plus antagonist treatment.
after progesterone (1600 h).

All animals were sacrificed 6 h

LH was measured by radioimmunoassay and

catecholamine concentrations in the MBH were determined with a
radioenzymatic assay.

G.

Statistical Analysis
Single factor or two-factor analysis of variance and Newman--Keuls

tests were applied to determine levels of significance in changes in LH
and LHRH secretion and catecholamine concentrations after experimental
drug treatment (187).

CHAPTER IV
RESULTS
Experiment 1:

Effects of PNMT and DBH inhibitors on LH and LHRH surges

induced by ovarian hormones.
As depicted in Figs. 1 and 2, the administration of progesterone at
1000 h to estrogen-pretreated rats significantly increased LHRH concen
trations in the median eminence at 1300 h.

This elevation was followed

by a significant decline at 14-00 h, and the levels did not change signi
ficantly thereafter.

As reported previously (190), peak LHRH concentra

tions occurred before the highest levels of LH.

Pretreatment with the

catecholamine synthesis inhibitors blocked or delayed the LH surge, but
had differential effects on the changes in median eminence LHRH.

Figure

1 shows that the EPI synthesis inhibitor SKF 64-139 partially blocked the
rise of LHRH seen at 1300 h.

In these animals, LHRH concentrations

increased significantly, but the magnitude of the effect was signifi
cantly less than that in the controls.

LHRH concentrations were similar

in the two groups at 14D0 and 1600 h.
In a second experiment, the highest levels of LH were observed in
the controls at 14-00 h.

Pretreatment with LY 78335, another EPI

synthesis inhibitor, appeared to delay the LH surge by 2h, at which time
LH concentrations were significantly higher than controls.

LY 78335-

treated animals also showed a similar delay in the elevation of LHRH
after progesterone treatment.
35
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Pretreatment with FLA-63, which inhibits both NE and EPI synthesis,
also abolished the ovarian hormone-induced LH surge, but in contrast to
the effects of SKF 64-139, completely prevented the rise of LHRH in the
median eminence (Table 1).

In this study, control animals showed signi

ficant increases in median eminence LHRH levels at 1400 and 1630 h com
pared to 1300 h valves.

However, after treatment with FLA-63, LHRH

levels failed to increase and progressively decreased from 1300 to 1630
h.
Thus, the LH surge can be prevented by inhibiting to synthesis of
NE or EPI but the synthesis of both NE and EPI must be prevented to
block the increase in LHRH concentrations in the ME.
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TIME

Figure 1. Effects of SKF 64139 on plasma LH and median eminence LHRH
concentrations, d, Time of drug administration; p, time of progesterone
administration. *P<0.05; **P<0.01 (vs. saline-treated controls, based
on analyses of variance and Newman-Keuls tests).
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Figure 2. Effects of LY78335 on plasma LH and median eminence LHRH
concentrations. Timing of injections is described in Fig. 1. *, P<
0.05, **, P< 0.01 (vs. saline-treated controls, based on analyses of
variance and Newman-Keuls tests).
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TABLE I
EFFECTS OF FLA-63 ON THE CONCENTRATIONS OF LH IN PLASMA (A) AND
LHRH IN THE MEDIAN EMINENCE (B)

A.
B.

1300

Time
1400

465±32
336±28

422±47
381±23

LH (ng/ml)
Saline
FLA-63
LHRH (pg/micg)
Saline

14.4-±1.9

22.4±2.6**

FLA-63

17.4-±1.5

16.4±1.4

1630

970±230**
382 ±50
26.6±3.0**
9.6±2.0***

Values are the mean ± SEM (n=10).
*P<p.01 vs. ail others, based on analysis of variance and Newman-Keuis
tests.
**P<0.01 vs. saline-treated group at 1300 h
***P<0.01 vs. saline treated group at 1630; P<0.05 vs. FLA 1300-treated
group.

Table 2 illustrates the effectiveness of the catecholamine synthe
sis inhibitors In reducing NE and/or EPI concentrations in the medial
preoptic nucleus.

The DBH inhibitor FLA-63 significantly decreased both

NE and EPI concentrations and significantly increased DA levels.
SKF 64-139 and LY 78334- decreased preoptic levels of EPI but had no
effect on NE or DA.

Both
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TABLE II
EFFECTS OF SKF 64139, LY 78335, AND FLA-63 ON
CATECHOLAMINE CONCENTRATIONS IN THE MEDIAL
PREOPTIC NUCLEUS

Treatment
Amine
Saline

FLA-63

SKF 64139

LY 78335
30.5±1.7
0.33±0.02*

NE
EPI

30.2±1.7
0.48±0.04

8.8±1.2*
0.22±0.04

25±1.6
0.28±0.03

DA

1.6±0.2

6.5±0.6*

1.2±0.09

1.7±0.1

Values are the mean ± SEM, expressed as picograms per microgram protein
(n = 25-26).
*P<0.01 based on analyses of variance and Newman-Keuls tests.

Experiment 2:

Effects of ovarian hormones oji catecholamine activity in

the hypothalamus.
Results from this study revealed that the estrogen plus
progesterone treatment that produces an LH surge, differentially
affected the steady state concentrations and extent of depletion of NE
and EPI in the POA and MBH.

As shown in Fig. 3, the aMT-induced decline

of EPI was significantly enhanced at 1300 h and at 1600 h in the MBH
after progesterone treatment.

There were no significant decreases in

EPI in the POA after aMT administration in rats treated with oil, or
estradiol and progesterone.

The ovarian hormones also produced small,
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Figure 3. Effects of estradiol plus progesterone (E + P) treatment on
the depletion of EPI in the MPO-AH and MBH after aMT treatment. *,
(MPO-AH), PC0.05 vs. oil-saline (SAL)-treated group; *, (MBH), P<0.05
vs. saline-treated group.

but significant, decreases in steady state EPI concentrations in the
POA.
Estradiol plus progesterone increased the magnitude of the
aMT-induced depletion of NE in both hypothalamic regions at 1300 h
(Fig. 4).

The turnover of NE was reduced to the oil vehicle levels at

1600 h in these areas.

Figure 4 also shows that basal, steady state

concentrations of NE were significantly decreased by the ovarian
hormones.
The levels and aMT-induced decline of DA were not affected in
either region by estrogen plus progesterone treatment (Table 3).

4-3

MPO-AH

1300

1600

Figure 4. Effects of estradiol plus progesterone (E + P) treatment on
the depletion of NE in the MPO-AH and MBH after aMT treatment. *,
P<0.05 vs. oil-saline (SAL)-treated group; **P<0.01 vs. saline-treated
group.

TABLE III

EFFECTS OF ESTRADIOL BENZOATE AND PROGESTERONE (EB & P)
ON THE LOCALIZED DEPLETION OF DA INDUCED BY aMT
IN THE POA AND MBH

POA

MBH

Treatment

Oil
**EB & P, 1300 h
**EB & P, 1600 h

Saline

aMT

Saline

aMT

317±53
24-1 ±22
306±37

172±36
165±20
170±28*

637±45
560±23
526±35

436±21
363±30
385±25*

Values are the mean ± SEM, expressed as picograms per mg (n = 9-10).
*P<0.05 vs. saline-treated group, based on analyses of variance and
Newman-Keuls tests.
*P<0.01 vs. saline-treated group, based on analyses of variance and
Newman-Keuls tests.

Experiment 3:

Effects o_f naioxone on LH release and catecholamine

turnover in the POA and MBH of estradiol-primed rats.
Naloxone administration to EB-pretreated rats significantly
increased circulating LH concentrations one hour later, as compared to
saline controls (Table 4).
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TABLE IV
EFFECT OF NALOXONE ON LH CONCENTRATIONS IN OVARIAN
HORMONE -TREATED RATS
Group
EB + saline
EB + naloxone

LH, ng/ml

335±52
608±43*

Values are expressed as ng/ml serum ± SEM in this and
subsequent Tables and Figures.
*P<0.01, t test
n=8-10

Figures 5 and 6 present the effects of naloxone on the aMT-induced
decline of NE and EPI, respectively, in the two diencephalic regions.
In the EB-saline controls, there were no significant declines in either
catecholamine levels 1 h after aMT, suggesting a low level of activity
in these regions.
However, the administration of aMT significantly increased the
depletion of NE in both the POA and MBH and also increased the decline
of EPI in the MBH of EB-naloxone treated rats, suggesting increased
catecholamine activity.

Naloxone did not alter the effects of aMT on

EPI or DA depletion in the POA (figs. 2, 3), but produced a small,
significant enhancement of DA depletion in the MBH (fig. 7).
Experiment 4:

Effects of morphine on LH release and catecholamine

turnover in the POA and MBH of EB-progesterone treated rats.
Table 5 shows that morphine decresed LH levels in EB-P treated
rats.

*
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Figure 5. Effects of naloxone (NAL) or saline (SAL) on the depletion of
NE after aMT in estradiol-primed rats. Statistical analysis (based on
2-factor analysis of variance and Newman-Keuls tests). MBH: *P<0.05
vs. respective saline, P<0.05 vs. EB and SAL-aMT. POA-AH: *P<0.01 vs.
respective saline, P<0.05 vs. EB and SAL-aMT.

MBH

EB&
SAL

EB&
NAL

Figure 6. Effects of naloxone on the depletion of EPI after ccMT.
Abbreviation, coding and statistical analysis as in figure 5. *P<0.
vs. respective saline and vs. EB and SAL-ctMT.
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MBH

Figure 7. Effects of naloxone on the depletion of DA after aMT
Abbreviations, coding and statistical analysis as in figure 5. MBH: **P
0.01 vs. respective saline; *P<0.01 vs. respective saline and PC0.05
vs. EB and SAL-aMT. POA-aMT. POA-AH: **P<0.01 vs. respective saline.

TABLE V
EFFECTS OF MORPHINE AND MORPHINE PLUS NALOXONE ON LH
CONCENTRATIONS IN OVARIAN HORMONE-TREATED
FEMALE RATS

LH, ng/ml + SEM

Group

EB +
EB +
EB +

progesterone + saline
progesterone + morphine
progesterone + morphine + naloxone

309 ± 84 * *
123±34
343 ± 62 * *

**P<0.01 vs. EB + progesterone + morphine, based on analysis of variance
and Newman-Keuls tests.

The catecholamine synthesis inhibitor, a-MT, produced significant
depletions of NE in the POA and MBH (fig. 8) and of EPI in the MBH
(fig. 9) in controls treated with estradiol and progesterone.

Figures 8

and 9 show that administration of morphine to such animals reduced NE
and EPI depletion by aMT in these areas, and also diminished the
decrease in MBH DA after aMT, suggesting decreased catecholamine turn
over in these regions.
Steady-state concentrations of catecholamines were not altered by
morphine with the exception of NE in the POA.

In this region, mor

phine-treated rats showed significantly decreased NE concentrations com
pared to the progesterone-saline group.
further by aMT.

NE levels were not decreased

Addition of naloxone at least partially antagonized
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PROG

PROG & PROG,
MOR MOR & NAL

Figure 6. Effects of morphine (MOR) and naloxone (NAL) on the depletion
of NE after aMT in animals pretreated with estradiol plus progesterone
(PROG). Statistical analysis as in figure 5. MBH: ***P<0.01 vs.
respective saline; **P<0.01 vs. PROG-aMT; *P 0.01 vs. respective saline,
*P 0.05 vs. respective saline.
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MOR

MOR&NAL

Fig. 9. Effects of morphine and naloxone on the depletion of EPI and DA
in the MBH. Abbreviations, coding, and statistical analysis as in
figjre 5. EPI results: *P<0.05 vs. respective saline; D*\ results:
**P<0.01 vs. respective saline; *P<0.05 vs. PROG-aMT and PROG, MOR and
NAL-aMT.
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these inhibitory effects of morphine.

Neither progesterone nor the

opiate drugs altered EPI or DA depletion in the POA.
Experiment 5:

Effects of GABA agonists and antagonists on LH secretion

in ovariectomized and ovariectomized, ovarian hormone-primed rats.
As presented in Table 6, administration of progesterone at 1000 h
to EB-primed rats markedly stimulated serum LH concentrations.
Treatment of steroid-primed rats at 1000 h and 1400 h with either
baclofen or muscimol prevented the rise in serum LH levels.

The GABA A

antagonist, bicuculline, failed to antagonize the inhibitory effects of
baclofen but reduced the effect pf muscimol on LH release.

The putative

GABA B antagonist, 5-aminovalerate, failed to antagonize baclofen's
inhibitory effect on the LH surge (Table 7).

A single injection of

baclofen given with progesterone, also significantly reduced, but did
not totally prevent, the LH surge produced by the ovarian hormone
regimen, while a single injection of muscimol was less effective.
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TABLE VI
EFFECTS OF BACLOFEN AND MUSCIMOL ON THE EB PLUS
P-INDUCED LH SURGE

Hormone Treatment

Oil and saline
EB + P + Saline
EB + P + Baclofen
(10 mg/kg x 1)
(10 mg/kg X 2)
+ bicuculline*
EB and P and muscimol
(2 mg/kg x 1)
(2 mg/kg x 2)
+ bicuculline#

LH (ng/ml)

n

400±27**
2202±273

24
25

1163 ±229**
129±28**
250±28**

10
13
7

1673±98
145±14**
808±170**

8
14
12

Ovariectomized rats received EB followed 4-8 h later by P (injections at
1000 h). Drug injections were given at 1000 h (x1 or at 1000 h (x2).
♦Baclofen (10 mg/kg) plus bicuculline (1 mg/kg) at 1000 h and 1400 h.
#Muscimol (2 mg/kg) plus bicuculline (1 mg/kg) at 1000 h and 1400 h.
**P<0.01 vs. EB + P+ Saline. *P<0.05 vs. EB + P + Muscimol x 2.
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EFFECTS OF 5-AMINOVALERATE (5AV) ON BACLOFEN'S
BLOCKADE OF THE LH SURGE

Treatment

EB
EB
EB
EB
EB
EB
EB
EB

+
+
+
+
+
+
+
+

LH (ng/ml)

Progesterone (Prog.)
Prog. + baclofen (10 mg/kg)
Prog. + baclofen + 5AV (10 mg/kg)
Prog. + baclofen + 5AV (25 mg/kg)
Prog. + baclofen + 5AV (50 mg/kg)
Prog. + baclofen + 5AV (75 mg/kg)
Prog. + baclofen + 5AV (125 mg/kg)
Prog. + baclofen + 5AV (150 mg/kg)

2373±873
207±25*
286±102*
103±13*
127±24-*
530±230*
154-±31*
130±23*

*P<0.01 vs. EB + Prog.
n=5-7

Table 8 shows that phenobarbltal administration to rats primed with
the ovarian hormones blocks the LH surge.

Concurrent injections of

bicuculline with phenobarbital, and by itself at 1400 h, failed to
reverse the barbiturate's effect.
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TABLE VIII
EFFECTS OF BICUCULLINE AND 5-AMINOVALERATE ON (5AV)

PHENOBARBITAL'S BLOCKADE OF LH SURGE

Treatment

EB
EB
EB
EB
EB
EB

+ Progesterone
+ Prog. + Phenobarbital (Pb) (50 mg/kg)
+ Prog. + Pb + bicuculline (2 mg/kg)
+ Prog. + Pb + bicuculline (4 mg/kg)
+ Prog. + Pb + 5AV (75 mg/kg)
+ Prog. + Pb + 5AV (150 mg/kg)

LH (ng/ml)

3799±1280
223±21*
177±22*
182±18*
205±39*
m±6*

*P<0.01 vs. EB + Prog
n=5-7

Table 9 shows that a 100 mg dose of synthetic LHRH produced a
dramatic rise in plasma LH concentrations within 15 minutes.
Administration of baclofen and muscimol, in doses that blocked the
progesterone-induced rise of LH, failed to affect this increase.

56
TABLE IX
EFFECTS OF BACLOFEN AND MUSCIMOL ON LH RELEASE INDUCED
BY ADMINISTRATION OF LHRH

Treatment

EB
EB
EB
EB

LH (ng/ml)

+ Progesterone (Prog.) + Saline
+ Prog. + LHRH
+ Prog. + LHRH + Baclofen
+ Prog. + LHRH + Muscimol

377±16
3342±332**
3378±538**
3967±372**

**P<0.01 vs. EB + P + saline
n=5-7

In a third study, baclofen and muscimol, in doses that blocked the
LH surge, did not significantly depress basal LH release in ovariectomized, hormonally untreated rats (Table 10).

A two-fold higher dose

of baclofen tended to depress LH levels, but the effect did not quite
reach statistical significance.

Bicuculline did not block and tended to

somewhat enhance baclofen's suppression of basal LH release.
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TABLE X
EFFECTS OF GABA AGONISTS ON LH RELEASE IN
OVARIECTOMIZED RATS

LH (ng/ml)

Treatment

Saline
Muscimol (2 mg/kg)
Muscimol (2 mg/kg)
and bicuculllne
Baclofen (10 mg/kg)
Baclofen (10 mg/kg)
and bicuculllne
Baclofen (20 mg/kg)
Baclofen (20 mg/kg)
and bicuculllne
Baclofen (20 mg/kg)
and bicuculline

609+30
501+76
(1 mg/kg)

435+31
531+65

(1 mg/kg)

507+33
443+54

(2 mg/kg)

390+46*

(4 mg/kg)

312+46**

*P<0.05, **P<0.01 vs. saline
n=5-8

Experiment 6:

Effects o_f GABA agonists on catecholamine turnover in the

POA and MBH of rats treated with ovarian hormones.
The synthesis inhibitor, aMT, produced significant depletion of NE,
EPI, and DA in the MBH (Fig. 10, 11, 12) and of NE in the POA (Fig. 10)
in control animals treated with EB followed by progesterone.

Admini

stration of baclofen or muscimol significantly decreased steady state
concentrations of NE and EPI in these regions.

In addition, aMT did not

significantly reduce NE and EPI after baclofen and muscimol pretreatment
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Figure 10. Effects of baclofen and muscimol on the depletion of
norepinephrine (NE) produced by aMT in the POA-AH and MBH.
*P<0.05, **P<0.01 vs. SALINE (SAL)

pg EPI/mg

SAUNE

BACLOFEN

MUSCIMOL

Figure 11. Effects of baclofen and muscimol on the depletion of
epinephrine (EPI) produced by aMT in the POA-AH and MBH.
*P<0.05 vs. SALINE (SAL)
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j
I

Figure 12. Effects of baclofen and muscimol on the depletion of dopa
mine (DA) produced by aMT in the POA-AH and MBH. **P<0.01 vs. respec
tive SAL.
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(Fig. 10 & 11), suggesting decreased catecholaminergic activity in these
areas.

These drugs did not alter the concentrations or depletion of DA

in either the MBH or POA (Fig. 12).
Experiment 7:

Effects o_f the GABAr agonist baclofen on the median

eminence accumulation of LHRH induced by progesterone.
As illustrated in Table 11, administration of progesterone at 1000
h to estradiol-primed animals significantly elevated plasma LH levels at
1400 h and 1600 h.

Treatment of ovarian hormone-primed rats with the

GABA B agonist, baclofen, drastically reduced LH concentrations at these
time periods.
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TABLE XI
EFFECTS OF BACLOFEN ON THE PROGESTERONE-INDUCED RISE
IN LH LEVELS IN ESTRADIOL-PRIMED RATS

LH (ng/ml)
Saline

Time
1100
1200
1300
U00
1600

h
h
h
h
h

222±26
187±39
240±62
938±62**
2873±599**

Baclofen
190±40
227±54
113 ±19
208±55*
72 ±8*

**P<0.01 vs. 1100, 1200, and 1300 h saline values
*P<0.01 vs. respective saline
n=7-9

Administration of progesterone at 1000 h to estradiol treated rats,
produced significant elevations in median eminence LHRH concentrations
at 1100 h.
1300 h.
again

LHRH concentrations declined significantly at 1200 h and

In rats pretreated with baclofen, the ovarian hormone priming
resulted in an increase in LHRH levels at 1100 h but levels did

not change significantly thereafter.
were significantly higher at 1400 h.

In fact, concentrations of LHRH
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TABLE XII
EFFECTS OF BACLOVEN ON THE PROGESTERONE-INDUCED ACCUMULATION
IN LHRH CONCENTRATIONS IN THE MEDIAN EMINENCE OF
ESTRADIOL-PRIMED RATS

LHRH (pg/microgram protein - ME)
Saline

Time
1000
1100
1200
1300
14-00
1600

h
h
h
h
h
h

29 ±2
4-2±3*
38 ±5
30±3**
21±3**
28 ±2

*P<0.01 vs. 1000 h saline control
**P<0.01 vs. 1100 h saline control
**P<0.05 vs. respective saline control
n=7-9

Baclofen

4-9±5
34-±9
35 ±5
3 7 +6 ***
33 ±5

Experiment 8a:

Effects of baclofen oji naloxone's enhancement of LH

release and catecholamine activity in estradiol-promed rats.
In the first study of Experiment 8, administration of naloxone to
estradiol-primed rats significantly elevated serum LH levels (Table
13).

Pretreatment, 30 minutes before naloxone, with baclofen failed to

affect the increase in LH release elicited by naloxone.
TABLE XIII
EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF LH RELEASE

Treatment

EB + Saline
EB + Naloxone (10 mg/kg) + Saline
EB + Naloxone + Baclofen (10 mg/kg)
** p<0.01 vs. EB + Saline control
* p<0.05 vs. EB + Saline control
n=7-8

LH (ng/ml)

123±12
277±32**
223±35*
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Tables 14-16 present the effects of naloxone on catecholamine
depletion induced by aMT in the MBH.

In the EB-saline controls, there

was no significant decline in either NE or EPI after aMT, suggesting a
low level of activity in these areas (Table 14 and 15).

However, admin

istration of naloxone significantly potentiated the depletion of NE and
EPI in the MBH, suggesting increased catecholamine turnover (Table 14
and 15).

Pretreatment with baclofen failed to prevent naloxone's

enhancement of NE or EPI depletion induced by aMT (Table 14, 15).
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TABLE XIV
EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF NE DEPLETION
INDUCED BY aMT IN THE MBH OF ESTRADIOL-PRIMED RATS

pg NE/mg tissue
Treatment

EB + Saline
EB + Naloxone
EB + Naloxone + Baclofen
*P<0.05 vs. EB saline
**P<0.05 vs. respective saline
n=7-8

Saline

776±155
1408±187*
1141±112*

aMT

481±111
758±113**
628±77**

67
TABLE XV
EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT OF
EPI ACTIVITY IN THE MBH

P9 EPI/mg tissue
Treatment

EB + Saline
EB + Naloxone
EB + Naloxone

*P<0.05 vs. EB saline
**P<0.05 vs. respective saline
n=7-8

Saline

oMT

19±5
40±5*
29 ±3

13±2
26 ±5*
20±3**
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TABLE XVI
EFFECTS OF BACLOFEN ON NALOXONE'S ENHANCEMENT
OF DA ACTIVITY IN THE MBH

pg DA/mg tissue
Treatment

EB + Saline
EB + Naloxone
EB + Naloxone + Baclofen

Saline

340±48
475±70*
650±43*

ocMT

163±42**
205±21**
168±22**

*P<0.05 vs. EB saline
**P<0.05 vs. respective saline
n=7-8
Experiment 8b;

Effects of nalmefene on the blockade of the LH surge

produced by baclofen.
The results from the second study in Experiment 8 are illustrated
in Table 17.

Administration of progesterone at 1000 h to estradiol

primed rats elicited a significant elevation of serum LH concentra
tions.

Pretreatment of ovarian hormone-primed rats at 1000 h and 1400 h

with baclofen significantly attenuated the LH surge.

Pretreatment with

nalmefene at 1000 and 1400 h did not significantly alter LH concentra
tions.

The concomitant administration of nalmefene with baclofen did

not prevent baclofen's inhibitory effect on the ovarian hormone-induced
surge of LH.
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TABLE XVII
EFFECTS OF NALMEFENE ON BACLOFEN'S BLOCKADE
OF THE LH SURGE

Treatment

EB
EB
EB
EB

+
+
+
+

Progesterone (Prog.)
Prog. + Baclofen (10 mg/kg)
Prog. + Nalmefene (10 mg/kg)
Prog. + Baclofen + Nalmefene

*P<0.01 vs. EB + Progesterone
n=6-8

LH (ng/ml)

2921±372
332±74*
2122±483
169±27*
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DISCUSSION
Experiments 1 and 2 were designed to define more completely the
role of the catecholamines, especially EPI in mediating the stimulatory
or positive feedback effects of the ovarian hormones on LHRH and LH
secretion.

Results from these studies suggest that both NE and EPI sys

tems are involved in the effects of estrogen and progesterone in stimu
lating the accumulation of LHRH in the median eminance and the release
of LH from the anterior pituitary.
Inhibition of both NE and EPI synthesis with the DBH inhibitor,
FLA-63, completely prevented the LH surge and accumulation of LHRH in
the median eminence that occur in the afternoon after progesterone
treatment.

These results are consistent with earlier work in which

administration of another DBH inhibitor, diethyldithiocarbamate, pro
duced similar effects on median eminence LHRH concentrations and pitui
tary LH release (190).

While these earlier results were attributed to

blockade of NE synthesis, the present studies indicate that a portion of
the inhibitory effect may be due to interference with EPI neurotransmis
sion.

Administration of the selective EPI synthesis inhibitor, SKF

64-139, partially blocked the progesterone-induced afternoon increase in
median eminence LHRH concentrations and prevented the LH surge.

Thus,

while depletions of both NE and EPI completely prevented the increase in
LHRH concentrations, selective depletion of EPI resulted in an increase
that was significantly smaller in magnitude than the control LHRH
value.

These findings indicate that both NE and EPI systems are acti

vated to produce the full accumulation of LHRH, and that under condi
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tions of reduced EPI neurotransmission, the smaller rise in LHRH concen
trations reveals that there is also a contribution of that neurotrans
mitter system.
The results obtained with the second EPI synthesis inhibitor, LV
78335, also support the conclusion that EPI neurons are involved in ova
rian hormone effects on LHRH and LH release.

Administration of LY 78335

interfered with progesterone effect to increase the accumulation of LHRH
in the median eminence and the pituitary release of LH, that is, the
increases in LHRH and LH release were delayed compared with those in the
concurrently run controls.

Indeed, rats treated with LY 78335 may have

shown a rebound phenomenon as levels of LHRH and LH were significantly
greater at 1600 h then the corresponding control values.

The two EPI

synthesis inhibitors exhibited different patterns of effects on LHRH.
This may reflect a shorter duration of neuroendocrine action for LY
78335 than SKF 64139, as suggested previously by the effects of these
two drugs on GH secretion (191).

However, it is evident from the

results of these studies that inhibition of EPI synthesis interferes
with the ovarian hormone stimulatory effects on LH and LHRH.
Despite a significant increase in median eminence LHRH concentra
tions, the administration of SKF 64139 totally prevented the subsequent
surge of LH induced by the ovarian hormones.

These effects of SKF 64139

are similar to those produced by the barbiturates which also block the
LH surge (192) but fail to prevent the increase in LHRH that precedes
the preovulatory or ovarian hormone induced LH surge (193,194).

The

significance of the sequential LHRH increase and decrease that occurs
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several hours after progesterone treatment is unclear.

Others have

proposed that the rise of LHRH may represent increased synthesis
(190,193), while a more recent report observed decreased degradation of
LHRH by an endopeptldase at this time (195).

The results of this and

other studies (190) suggest that the elevation of LHRH In the median
eminence is dependent upon catecholamine neurotransmission and appears
to be necessary, but not sufficient, for the subsequent LH surge.
However, the physiological significance of the decline in LHRH levels
that follows the elevation is not clear.

It is probable that this

decrease is not a release of the neuropeptide into portal blood that
triggers the LH surge, because it may occur in the absence of LH release
e.g. after blockade by barbiturates or SKF 64-139.

The release of LHRH

that initiates or maintains the LH surge may occur after the decline and
is more likely regulated by both NE and EPI systems.
The pharmacological characterization of neurotransmitters involved
in ovarian hormone feedback is limited by the selectivity and spe
cificity of the agents used.

In addition to its PNMT-inhibLting

actions, SKF 64-139 possesses some alpha2-adrenergic blocking effects,
but those are unlikely to account for its inhibitory actions on LH and
LHRH surges.

First, a non-alpha-blocking PNMT inhibitor also prevents

ovarian hormone-induced elevation of LH release (92).

The rises in LHRH

and LH concentrations were also inhibited by LY 78335, a PNMT inhibitor
with little demonstrable alpha-blocking action in vivo (205).

Further

more, PNMT inhibitors do not share the effect of alpha-noradrenergic
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antagonists in disrupting episodic LH release or preventing the eleva
tion of PRL by estradiol (92).

The present results also demonstrate a

further difference between pharmacological noradrenergic and adrenergic
antagonists, as the DBH inhibitor FLA-63 abolished the rise in LHRH and
lowered its concentration, while the PNMT inhibitor did not.

Therefore,

it is more likely that the neuroendocrine effects of LY 78335 and SK & F
64-139 are due to disruption of EPI rather than NE neurotransmission.
Experiment 2 was designed to examine whether an ovarian hormone
regimen that elicits an LH surge enhances the activity of NE and EPI
neurons in the MBH and POA.

This and subsequent studies, in which NE

and EPI activity was of importance, employed the alpha methyltyrosine
method to determine catecholamine turnover.

That is, the degree of

depletion of a catecholamine after synthesis inhibition with alpha
methyltyrosine was taken as an index of the activity of that neurotrans
mitter system.

The results also support the hypothesis that central EPI

neurons participate in the regulation of LH and LHRH release.

The

depletion of MBH EPI induced by the catecholamine synthesis inhibitor
oMT was potentiated by the estrogen plus progesterone regimen that
induced an LH surge.

It is generally accepted that such enhanced deple

tion reflects an increased degree of nerve impulse flow in the system
(185) and these findings, therefore, suggest that there is increased
activity in medial basal hypothalamic EPI nerve terminals during the LH
surge induced by the ovarian hormones.
not alter EPI depletion in the POA.

Estradiol and progesterone did

Similarly, an earlier report

observed no changes in EPI turnover in the medial preoptic nucleus
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during the proestrus critical period (108).

Although the results are in

contrast to a recent study reporting increased POA EPI turnover
coinciding with the proestrus surge of LH (116) the results of the
present studies suggest that EPI may promote the release of LHRH from
nerve terminals in the MBH region.

This conclusion is supported by the

demonstration that EPI evokes the release of LHRH from the median
eminence jji vitro (206).
Because the pharmacological studies suggested that both NE and EPI
systems may also be activated during the accumulation of LHRH that pre
cedes the LH surge, the depletion of the catecholamines after aMT treat
ment were assessed at an earlier time point that approximately corres
ponds to these events, based on the results from Experiment 1.

Consis

tent with the pharmacological results, EPI depletion was enhanced only
in the MBH during the earlier period.

In addition, the aMT-induced

decline of NE was maximal at this time in both the POA and MBH.

These

results are consistent with several investigators who have observed
increased NE turnover in the MBH and POA associated with the proestrus
or ovarian hormone induced LH surge (104,105,106,110).

Moreover, these

results are also consistent with previous proposals that there are timedependent increases in hypothalamic catecholaminergic activity that
mediate the effects of ovarian hormones on LHRH and LH release (91).
The results from Experiments 1 and 2 suggest that the ovarian hor
mones differentially affect NE and EPI systems in different regions of
the hypothalamus.

The elevation of NE turnover by the ovarian hormones

at 1300 h in both the POA and MBH may possibly reflect the importance of

75
NE in the ovarian hormone-induced accumulation of LHRH in the median
eminence.

In contrast to NE, the estradiol plus progesterone treatment

enhanced EPI turnover only in the MBH but at 1600 h as well as 1300 h.
Although both NE and EPI seem to be involved in activating LHRH accumu
lation at 1300 h, EPI may be the neurotransmitter primarily involved in
promoting the release of LHRH at 1600 h that is directly involved in
initiating the LH surge.
In summary, the results from Experiments 1 and 2 support the hypo
thesis that both NE and EPI systems have roles in regulating the secre
tion of LH.

These results indicate that 1)

activation of both EPI and

NE neurons mediates the accumulation of LHRH in the median eminence that
precedes the ovarian hormone-induced Lh surge; and 2)

EPI and NE sys

tems are also involved in the ovarian hormone-induced LH surge.
The neurochemical mechanisms by which the ovarian hormones modulate
noradrenergic and adrenergic systems to regulate LH secretion is not
well understood.

The ovarian hormones are apparently not taken up by

LHRH cell bodies (207).

Even though there does appear to be some degree

of uptake into catecholamine cell bodies (208), the ovarian hormones
seem to affect catecholamine turnover only in specific regions of the
brain (110) such as the P0A and MBH, areas that contain catecholamine
nerve terminals.

Thus, the ovarian hormones may affect some process

that locally controls the turnover of these neurotransmitters at the
nerve terminals.

Experiments 3 and 4- examined the possibility that the

endogenous opioid neuropeptides may participate in locally modulating
catecholamine turnover.

Therefore, Experiments 3 and 4 were designed to
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test whether the opiate antagonist, naloxone, and the opiate agonist,
morphine, which have well defined effects on gonadotropin secretion,
alter the activity of NE and EPI neurons in the hypothalamus of ovarian
hormone treated rats.

The results of these studies provide support for

the hypothesis that opiate effects on LH secretion are mediated by
alterations in catecholamine neurotransmission.

In Experiment 3, admi

nistration of the opiate antagonist, naloxone, increased LH levels,
potentiated the decline of NE in the POA and MBH, and enhanced the
depletion of EPI in the MBH after aMT.

These findings suggest that

naloxone enhances activity in noradrenergic and adrenergic systems that
innervate the POA and MBH.

This conclusion is strengthened by the

results of previous pharmacological studies demonstrating thatnaloxoneinduced LH release is prevented by noradrenergic and/or adrenergic syn
thesis inhibitors (H5, 147).

The catecholamine systems that are acti

vated by the removal of opiate inhibition may, in turn, enhance the
release of LHRH (92,190).
It is possible that naloxone increases NE and EPI activity by anta
gonizing the inhibitory influence of an endogenous opioid neuropeptide.
Opiate alkaloids and neuropeptides depress the release of NE from corti
cal, cerebellar, and hypothalamic slices in vitro (136,137), and the
results of Experiment 4- demonstrate that the opiate agonist, morphine,
may reduce NE and EPI release in discrete hypothalamic regions as well.
The administration of morphine to ovariectomized rats primed with ova
rian hormones decreased LH, and also reduced the depletion of NE in the
POA and MBH and of EPI in the MBH, after aMT, suggesting reduction of
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catecholamine activity during the depression of LH release.

Morphine

also decreased steady-state concentrations of NE in the POA, an effect
possibly reflecting a decrease in synthesis.

This effect was prevented

in most cases by the coadministration of naloxone, implicating opiate
receptor involvement in the effect of morphine.

Previous studies have

shown that morphine prevents the ovarian hormone-induced accumulation of
LHRH in the median eminence (14-1) as well as the release of LHRH into
pituitary portal blood on proestrus afternoon (138).

These results

indicate that one possible mechanism by which the opiates disrupt LH
secretion may be through inhibition of hypothalamic noradrenergic and
adrenergic systems that regulate LHRH synthesis and/or release.
In Experiment 4-, morphine also decreased the aMT induced depletion
of DA in the MBH.

A number of studies have also shown that morphine and

endogenous opioid peptides such as beta-endorphin reduce the turnover of
DA in the median eminence and diminish the release of tuberoinfundibular
DA into hypophysial portal circulation (209).

Although confusion

remains as to the role of these changes in LH secretion, there is more
evidence linking them to the release of prolactin by morphine (209).
It is interesting to note the similar neuroendocrine and neurochemical actions of naloxone and progesterone.

Both stimulate LH

release in ovariectomized, estrogen-primed rats and these effects are
dependent upon catecholaminergic neurotransmission (14-1,14-5,147).

More

over, both progesterone and naloxone stimulate the otMT-induced depletion
of EPI in the MBH, but not POA, and of NE in the POA and MBH.

These

observations are therefore consistent with the hypothesis that one
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aspect of ovarian hormone positive feedback may involve removal of the
inhibitory influence of an endogenous opioid system over catecholamine
release.

Similarly, morphine may stimulate the opioid receptors for

such a system that are located on NE and EPI nerve terminals.
Progesterone and naloxone differ, however, in the time course of
these effects.

Progesterone may require several hours to stimulate LH

release if the hormone is acting via classic steroid receptor mecha
nisms, involving genomic expression, that result in depression of activ
ity of an endogenous opioid neuropeptide system, and subsequent stimu
lation of catecholamine release.

Presumably, the opiate antagonist,

naloxone, stimulates LH and catecholamine release with shorter latentcy
because this drug directly reduces endogenous opioid neurotranmission,
bypassing the steroid receptor system.
A number of recent studies have attempted to define what changes,
if any, occur in brain, pituitary, and plasma beta-endorphin concentra
tions in naturally cycling animals and if these pools of beta-endorphin
are responsive to ovarian hormone treatment.

An initial report noted

that median eminence beta-endorphin concentrations increase while
arcuate levels of beta-endorphin decrease on proestrous afternoon
(196).

However, hypothalamic beta-endorphin concentrations do not

appear to differ from diestrus to proestrus (197) and a more detailed
analysis of beta-endorphin content in hypothalamic nuclei during the
estrous cycle revealed a significant increase in arcuate beta-endorphin
levels during proestrus (198).

Thus, attempts to relate changes In beta-endorphin concentrations
in the hypothalamus with pituitary function have been inconclusive and
require further investigation.
Beta-endorphin levels appear to vary in hypophyseal portal blood
during the menstrual cycle (199), being high during the follicular and
luteal phase and virtually undetectable at menstruation or after long
term ovariectomy.

These results would suggest that when ovarian hormone

concentrations are low, such as after ovariectomy or during menstrua
tion, hypothalamic beta-endorphin release is correspondingly low (199).
These results are interesting in view of other reports noting naloxone's
inability to stimulate LH release at times when ovarian hormone concen
trations are low, such as after gonadectomy (200), during the early fol
licular phase of the menstrual cycle in normal women (201,202), or in
post-menopausal women (203).

Conversely, the opiate peptide FK 33-824-

fails to inhibit LH release one week after gonadectomy (200).

Thus, a

great deal of evidence exists to support a physiological relationship
between the ovarian hormones and the endogenous opioid peptides in the
regulation of the pituitary gonadotropin secretion.
In summary, the results from Experiment 3 and 4- support the hypo
thesis that the ovarian hormones produce their stimulatory feedback
effects on LH secretion by altering the activity of an inhibitory endo
genous opioid neuropeptide system which, in turn, regulates the release
of NE and EPI.

These catecholamines are then able to stimulate LHRH,

and subsequently, the LH surge.
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A scenario, virtually identical to the hypothesis discussed above,
has, in fact, been recently reported (91).

This proposed role for the

opioid neuropeptides is complemented by a very similar role in the nega
tive feedback effects of estradiol in female rats (211) and testosterone
in male rats (210).

In both of these cases it is evisioned that the

hormone (either estradiol or testosterone) activates an endogenous opi
oid peptide system that, in turn, inhibits LH secretion (210,211).

In

the model employed in these studies, progesterone may act to physiolo
gically reverse these negative feedback effects of estradiol in order to
trigger the preovulatory release of LH.
Few studies have addressed the issue of which endogenous opioid
peptide(s) the ovarian hormones interact with to regulate LH release.
The evidence presently available suggests that beta-endorphin and/or
dynorphin peptide may mediate these ovarian hormone effects.

Although

met-enkephalin levels are responsive to chronic estrogen treatment (212)
in male rats, hypothalamic concentrations of met-enkephalin do not
appear to fluctuate during the estrous cycle (213).

Perhaps more impor

tantly, antisera against beta-endorphin, and to a lesser extent, anti
sera against dynorphin 1-13 increase LH release when injected into the
MBH of immature female rats (214).

In contrast, antiserum against met-

enkephalin do not affect LH release in this model (214).

A role for

dynorphin in the control of LH release is further supported by the find
ing that bremazocine, a benzomorphan compound selective for kappa recep
tors, is more potent than morphine as an inhibitor of LH release (215).
Therefore, an opioid peptide of the beta-endorphin and/or dynorphin
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family may mediate ovarian hormone effects on gonadotropin secretion.
However, only more intensive research of all the opioid neuropeptides,
including met-enkephalin, will clearly answer this important question.
As has been detailed in the Introduction of this dissertation, GABA
may also be considered a candidate for a neuromodulatory role in locally
controlling hypothalamic catecholamine activity and pituitary LH secre
tion.

Therefore, Experiments 5 and 6 were designed to examine the

effects of GABA agonists and antagonists on LH secretion under a variety
of endocrine conditions and also to test whether GABA agonists depress
activity of NE and EPI neurons after synthesis inhibition in discrete
regions of the hypothalamus.

The results of Experiment 5 and 6 raise

the possibility that a GABA system exists in the hypothalamus capable of
inhibiting adenohypophyseal LH secretion, perhaps by depressing activity
in central NE and EPI neurons.

Administration of the GABA agonists,

baclofen and muscimol, prevented the LH surge in rats induced by the
sequential pretreatment of estradiol plus progesterone.

Maximal inhibi

tion was reached when a second injection of baclofen or muscimol was
given 4 h after the first.

The effect of the GABA agonists to disrupt

the LH surge appears to occur in the brain, as neither baclofen nor mus
cimol affected the release of LH in response to administration of syn
thetic LHRH.
Baclofen and muscimol also tended to depress LH levels in ovariectomized, hormonally untreated rats, an effect that is more pronounced
following central administration of GABA or muscimol (175).

It is

unclear why the GABA antagonist, bicuculline, potentiated this effect,
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although it is possible that under these circumstances, a stimulatory
GABA component may be unmasked (172).
The barbiturate, phenobarbital, has a well known inhibitory effect
on the LH surge (192, 193, 194).

Because phenobarbital appears to

enhance the binding of GABA to its receptor and also enhances Cl ion
conductance, it was possible that the barbiturate effect on LH was medi
ated by GABA systems.

This, however, appears not to be the case as the

GABA antagonist, bicuculline, did not prevent phenobarbital's blockade
of the LH surge.

Barbiturates may therefore directly affect catechola

mine transmission to disrupt LH release (193, 194).
The results from Experiment 6 provide further evidence as to pos
sible sites and mechanisms of action of this inhibitory GABA effect on
LH release.

As demonstrated in Experiment 2 and 5 aMT produced signifi

cant decreases of NE in the POA and of NE, EPI, and DA in the MBH of
animals pretreated with estradiol followed by progesterone.

Administra

tion of the GABA agonists, baclofen and muscimol, produced similar
effects on catecholamine activity as both GABA agonists significantly
reduced steady state levels and blunted the aMT-induced decline of NE in
the POA and of both NE and EPI in the MBH.

In contrast, the GABA

agonist did not affect the levels or depletion of DA in the MBH.

These

results suggest that noradrenergic and adrenergic neurotransmission in
these areas was reduced by GABA stimulation, while DA activity was
unaffected.

Previous reports and the results from Experiments 1-4 have

demonstrated the importance of NE and EPI activity for the ovarian
hormone-induced rise in median eminence LHRH and the subsequent LH surge
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(91, 190).

GABA systems may therefore disrupt LH release by depressing

activity in the NE and EPI nerve terminals innervating the POA and MBH
that regulate these events.
Several lines of evidence support such a role for GABA.

GABA

depresses NE release in brain and from peripheral nerves via actions at
a receptor subtype different from classical postsynaptic receptor (167,
168).

Pharmacological characterization of this GABA B receptor reveals

that 1) baclofen is a potent agonist at this receptor subtype, but not
at the postsynaptic GABA A receptor (168); 2) muscimol also possesses
some GABA B as well as GABA A activity (154, 161); 3) the GABA B is
insensitive to antagonism by bicuculine (159, 160).

The actions of

these drugs on the GABA B receptor therefore closely parallel their
actions on LH release.

Interestingly, bicuculline, in a dose known to

antagonize GABA A receptors (160), failed to block the inhibitory effect
of muscimol on LH release.

This raises the possibility that some GABA A

effects may contribute to muscimol's depression of LH release.

In other

studies, the selective GABA A agonist, Thip (4,5,6,7-tetrahydroisoxazole
(5,5-6) pyridin-3-ol) either failed to block or had inconsistent effects
on LH release, providing further support for GABA B mediation of bac
lofen and muscimol effects on LH secretion and catecholamine activity.
In contrast to the GABA A-mediated opening of chloride ion channels
in postsynaptic membranes (149), B receptors have recently been linked
to inhibition of calcium influx in presynaptic nerve terminals (155,
156, 157).

This mechanism, therefore, could possibly account for the

lowering by baclofen and muscimol of NE and EPI concentrations as well
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as the blockade of the aMT-induced depletion of these catecholamines
observed in Experiment 6.

The activity of tyrosine hydroxylase, the

rate limiting enzyme in catecholamine synthesis, is increased by calcium
in noradrenergic neurons (216), and activation of GABA B receptors by
baclofen and muscimol to effectively diminish calcium conductance could
thus reduce nerotransmitter synthesis and decrease steady state levels
of the catecholamines.

Moreover, it is well established that increased

intracellular calcium is essential for the release of catecholamines and
other neurotransmitters (217).

The depression of calcium influx by

stimulation of GABA B receptors might therefore reduce NE and EPI
release and consequently, the decline of these catecholamines after
inhibition of synthesis, an effect that depends on the release of
catecholamine release (185).
The hypothesis of GABA B receptors located on NE and EPI nerve ter
minals also receives support from the recent demonstration that a subpo
pulation of GABA B receptors is associated
nerve terminals (21B).

with cortical noradrenergic

The regional and neurochemical specificity of

the effects of GABA agonists on catecholamine activity in Experiment 6
is consistent with Experiments 2-4 which found that NE in both the POA
and MBH is responsive to treatments with ovarian hormones and opiate
drugs, while the EPI systems are affected only in the MBH.

The absence

of an effect of baclofen on MBH DA activity has also been observed pre
viously (219).
GABAergic suppression of central NE activity has also been demons
trated using ovariectomized rats (173, 174), and on the basis of such
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effects it has been proposed that such a localized control mechanism may
contribute to the inhibitory effects of estrogen on LH release (173,
174).

Although few studies have correlated ovarian hormonal effects on

LH with changes in central GABA activity, a recent report (175) found
that an estrogen treatment that reduced LH also increased GABA turnover
while decreasing NE turnover in the medial preoptic area.

Moreover,

the GABA synthetic enzyme, GAD, is responsive to estradiol treatment
(178) and hyperprolactinemia, which suppresses both LH release and NE
activity (220), also increased GAD activity (177) and GABA turnover
(221).

It is interesting, in view of these reports, to note that some

GABA neurons in the preoptic area accumulate estradiol (176).
In summary, the results from Experiments 5 and 6 support that the
hypothesis that estradiol and progesterone affect activity in intrahypothalamic GABA systems that regulate ascending catecholamine input to
LHRH neurosecretory cells to affect LH release.

Experiment 7 was

designed to examine whether a GABA agonist, which blocks the LH surge,
also prevents the accumulation of LHRH in the median eminence induced by
administration of stiulatory estradiol plus progesterone regimen.
As observed in Experiment 1, and reported previously (190), admin
istration of progesterone to estradiol-primed rats elicits a significant
increase in median eminence LHRH concentrations at 1100 h.

LHRH concen

trations decreased significantly at 1300 and 1400 h and did not change
significantly thereafter.

Treatment of ovarian hormone-primed rats with

baclofen, in a dose that markedly suppressed the LH surge, had a dif
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ferent pattern of effects on LHRH levels.

Levels of LHRH were increased

at the 1100 h time point but did not change significantly thereafter.
In fact, LHRH concentrations were higher at every time point in
baclofen-treated rats as compared to control animals although only the
1400 h time point reached statistical significance.

Thus, it appears

that baclofen allows progesterone to stimulate LHRH accumulation in the
median eminence, yet prevents the subsequent decline in LHRH levels.
The result that in baclofen-treated rats LHRH did not decrease
significantly after peaking at 1100 h, and that levels at 1400 h were
significantly higher than controls, may possibly reflect a decrease in
LHRH release.

An effect of baclofen to decrease LHRH release would be

consistent with the evidence presently available that baclofen reduces
calcium conductance in presynaptic nerve terminals (155, 156, 157)
andsuch a mechanism has been suggested to account for baclofen's
depression of monoamine release in the brain (154, 168) and periphery
(159, 164, 167).
Experiment 8 was designed to test whether baclofen reverses the
stimulatory effects of naloxone on LH release and catecholamine activity
and also to examine whether nalmefene prevents the blockade of the LH
surge produced by baclofen.

The results from Experiment 8 provide

preliminary evidence for parallel, independent modulation of LH
secretion and hypothalamic catecholamine activity by GABA and opioid
peptides.

In the first study of Experiment 8, pretreatment of

estradiol-primed rats with baclofen failed to prevent the enhancement of
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LH by naloxone.

In addition, the GABA agonist failed to reverse

naloxone's enhancement of NE or EPI depletion in the MBH induced by
aMT.

These results therefore suggest that the effects of naloxone on

LH release and catecholamine activity are not due to interruption of
opioid-GABA links.

That is, opioid neuropeptides do not appear to

stimulate the activity of central GABAergic neurons in order to affect
hypothalamic catecholamine activity and pituitary LH release.
Experiment 8b was designed to test whether the long acting opiate
antagonist, nalmefene, could, when administered simultaneously with
baclofen, reverse the GABA agonist's blockade of the LH surge.

In this

study, treatment with nalmefene could not prevent the blockade by
baclofen of the ovarian hormone-induced LH surge.

These results thus

suggest that baclofen does not disrupt LH secretion by enhancing an
opioid peptide inhibitory influence over LH release.

Moreover, further

preliminary evidence is then provided in support of two parallel yet
independent intrahypothalamic systems that regulate gonadotropin
secretion and hypothalamic catecholamine activity.
The mechanisms through which NE and EPI act in mediating ovarian
hormone effects on LHRH and LH release have been partially
characterized.

The majority of studies have implicated alpha-adrenergic

(but not beta-adrenergic) receptors in NE and EPI actions (97, 222).
Several recent studies suggest that these alpha-receptors may be of the
alpha 1 type, presumably post synaptic (89, 116, 222).

For example,

phenylephrine (alpha 1 agonist) and clonidine (alpha 2 agonist) both
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increase LH release in ovariectomized rats primed with estrogen and pro
gesterone (89).

The preovulatory (116) or estrogen-induced LH surge

(222) is blocked by the alpha 1 antagonists prazosin and phenoxybenzamine (116).

Although both alpha 1 and alpha 2 receptors seem to be

involved, these results provide preliminary support for a primary role
for alpha 1-adrenergic receptors in the stimulation by noraderenrgic and
adrenergic systems of LHRH and LH.
The ovarian hormones

may regulate monoamine neurotransmission

through mechanisms other than those affecting synthesis and release.
For example, minor effects of ethinyloestradiol to decrease NE re-uptake
in the hindbrain have been reported (223).

Also, enzymes involved in

monoamine degradation, such as type A monoamine oxidase, appear to be
responsive to ovarian hormone treatment (224).

Ovarian hormones may

also modulate monoamine neurotransmission postsynpatically, e.g. by
affecting the quantity or affinity of neurotransmitter receptors (59).
However, although ovarian hormones effects on neurtransmltter re-uptake,
degradation, and receptor quantity may participate in the regulation of
reproductive function, these mechanisms do not account for discrete
effects of estradiol and progesterone to affect monoamine turnover only
in specific regions of the brain.

For this reason, it has been proposed

that the ovarian hormones may affect the activity of neuroregulatory
substances in the hypothalamus that modulate catechoamine activity and
anterior pituitary LH secretion.
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SUMMARY
Previous research has demonstrated the importance of monoaminergic
neurons in mediating the stimulatory feedback effects of the ovarian
hormones on hypothalamic LHRH concentrations and adenohypohyseal LH
secretion.

Results from Experiments 1 and 2 strongly suggest that brain

epinephrine, in addition to norepinephrine, may mediate a portion of
ovarian hormone effects on LHRH and LH.
The stimulatory feedback effects of estradiol and progesterone
appear to be exerted, at least in part, through activation of POA and
MBH noradrenergic and MBH adrenergic systems.

These neuro-chemical

changes then seem to facilitate LHRH, and subsequently LH, release.
The neurochemical mechanisms have not been established for these
discrete ovarian hormone feedback actions on NE and EPI neurotransmis
sion.

Because estradiol and progesterone appear to alter NE and EPI

turnover primarily in areas containing the nerve terminals for these
neurotransmitters, the possibility that the ovarian hormones affect that
activity of neuromodulatory substances was addressed.

Results from

Experiments 3-7 support the concept that the ovarian hormones produce
their positive feedback effects, in part by reducing activity in hypo
thalamic opioid neuropeptide and GABA neurons which, in turn, dlsinhibit
stimulatory NE and EPI inputs to LHRH neurons.

This facilitation of

LHRH release would allow the subsequent LH surge to occur.
Results from Experiment 8 provide preliminary evidence that these
regulatory effects of opiates and GABA are actions of parallel,

independent systems controlling catecholamine activity and anterior
pituitary LH release.
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